| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Coherus Oncology, Inc.$1.54
-0.09 (-5.52%)
B 60Pipeline Score Undervalued Biotech · Commercial
Market Cap
248.34 M
EPS
-1.25
P/E Ratio
-
Value Trade
1.54 M
SEC Financials
Q1 2026Dilution Risk
Revenue
12.31 M
R&D Expenses
21.54 M
Operating CF
-57.89 M
Total Assets
266.02 M
Total Liabilities
187.40 M
Equity
78.62 M
D/E Ratio
12,345
0 %
Week
-12.97 %
1 Month
-5.29 %
3 Month
47.71 %
6 Month
-88.32 %
5 Year
-87.37 %
All Time
Cash Data
Cash Position
167.05 M
Monthly Burn
19.30 M
Runway
6.7 mo
Burn Trend
SEC Filing
May 11, 2026
Overview
Volume
930.77 K
52 Week Range
0.71 - 2.62
% held by Insiders
24.85 %
% held by Institutions
35.6 %
Enterprise Value
135.67 M
Total Shares
154.16 M
Short %
19.28 %
Float Shares
134.74 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Coherus Oncology, Inc.
729Total events
4Upcoming
273Tier-1 (high impact)
2014 – 2028Coverage
Upcoming catalysts 4
Sep 30, 2026
T2Milestone Payment
First earnout payment milestone: UDENYCA net sales >= $300M over four consecutive quarters from July 1, 2025 through September 30, 2026
Event history 725
Q3 2026
●Trial InitiationpasritamigTrial
Anticipate initiating pasritamig combination study in mCRPC in the fall
metastatic castration-resistant prostate cancer (mCRPC)source ↗
Jun 2026
◆Topline ReadoutCasdozokitugClinical Data
Initial data from 1L HCC Phase 2 study expected around mid-year 2026
first-line unresectable hepatocellular carcinoma (uHCC)source ↗
May 11, 2026
May 11, 2026
▲Enrollment CompleteCasdozokitugTrial
Patient accrual complete for 1L HCC Phase 2 randomized clinical trial for casdozokitug
first-line unresectable hepatocellular carcinoma (uHCC)source ↗
Q2 2026
◆Trial InitiationtagmokitugTrial
Initiation of combination study with J&J's T-cell engager pasritamig in mCRPC expected in H2 2026
metastatic castration resistant prostate cancer (mCRPC)source ↗
Mar 9, 2026
◆Quarterly UpdateCorporate
Full year and Q4 2025 financial results release and conference call
Feb 23, 2026
Feb 17, 2026
▼Equity OfferingCorporate
Closing of underwritten public offering of 28,600,000 shares at $1.75 per share
Feb 12, 2026
▼Equity OfferingCorporate
Pricing of underwritten public offering of 28,600,000 shares at $1.75 per share
Jan 13, 2026
◆Oral PresentationPresentation
Coherus management to present at 44th Annual J.P. Morgan Healthcare Conference
Q1 2026
◆Topline ReadoutCasdozokitugClinical Data
First data readout expected from Phase 2 randomized trial of casdozokitug/toripalimab/bevacizumab in 1L HCC
1L hepatocellular carcinoma (HCC)source ↗
2026
◆Topline ReadouttagmokitugClinical Data
Multiple 2026 clinical readouts expected for tagmokitug
advanced solid tumors (head and neck squamous cell carcinoma, colorectal cancer, gastric cancer, esophageal cancer)source ↗
Drug Pipeline Intelligence
B60
Pipeline Score $2.8B
Pipeline ValueUndervalued
Valuation Signal14
Drugs Scored11.3x
rNPV / MCap Top 88%
Micro Cap (rank 110 of 912)
Percentile RankCoherus Oncology, Inc. holds a solid B-grade pipeline (60/100), with $17.0B risk-adjusted pipeline value, led by CHS-0214 in Plaque Psoriasis (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CHS-0214 Small molecule | Rheumatoid Arthritis | Phase 3 | NCT02115750 | 58% | $5.0B | COMPLETED | 1,006 | - | - | May 1, 2016 | - | Jun 26, 2019 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
tagmokitug | solid tumors | Phase 1b/2a | 2026-01-05 | picomolar affinity for CCR8; no off-target binding; selective reductions in CCR8+ Tregs Read More | Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114) Read More | |
tagmokitug | solid tumors | Phase 1b/2a | 2026-01-05 | picomolar affinity for CCR8; no off-target binding; selective reductions in CCR8+ Tregs Read More | Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114) Read More | |
tagmokitug | solid tumors | Phase 1b/2a | 2026-01-05 | picomolar affinity for CCR8; no off-target binding; selective reductions in CCR8+ Tregs Read More | Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114) Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CHRS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CHRS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CHRS▲ +11.4%on this news
Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update - LOQTORZI net revenue of $11.8 million in Q1 2026 - - Patient accrual complete for 1L HCC Phase 2 randomized clinical trial for
Coherus Oncology announced its financial results for Q1 2026, revealing a net revenue of $11.8 million from LOQTORZI. The company completed patient accrual for its first line hepatocellular carcinoma Phase 2 trial of casdozokitug. Coherus also highlighted updates on the developmental progress of tagmokitug, describing its safety and immune response benefits, while addressing ongoing financial losses and reduced R&D expenses.
Read more →CHRSCoherus Oncology to Report First Quarter 2026 Financial Results on May 11, 2026
Coherus Oncology, Inc. will release its first quarter 2026 financial results on May 11, 2026, after market close. A conference call and webcast will follow at 5:00 p.m. Eastern Time to discuss the results and provide a business update. The company is focused on advancing its oncology pipeline, which includes several mid-stage clinical candidates.
Read more →CHRS▲ +6%on this news
Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update - LOQTORZI net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 - - Reduced secured a
Coherus Oncology reported a significant increase in LOQTORZI sales for the full year 2025, with net revenues reaching $40.8 million. The company has effectively reduced its debt from $480 million to $38.8 million over the past two years. Despite revenue growth, Coherus continued to incur noteworthy net losses for both the fourth quarter and the entire year. The company remains focused on advancing its promising pipeline candidates with expected clinical data releases in 2026.
Read more →CHRSCoherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026
Coherus Oncology, Inc. will release its full year and fourth quarter 2025 financial results on March 9, 2026. Following the release, the management team will host a conference call and webcast to discuss the results and provide a business update. The company is focused on growing its oncology product sales and advancing its clinical pipeline.
Read more →CHRSCoherus Oncology to Participate in Upcoming Investor Conferences
Coherus Oncology announced its participation in upcoming investor conferences, where senior management will present. The presentations will be available via webcast, and replays will be accessible for 90 days. The company is focused on advancing its oncology pipeline, including LOQTORZI and other clinical candidates targeting various cancers.
Read more →CHRSCoherus Oncology, Inc. Announces Closing of Public Offering of Common Stock
Coherus Oncology, Inc. has successfully closed a public offering of 28.6 million shares of common stock at $1.75 per share, raising approximately $50.1 million. The funds will be used to support the commercialization of LOQTORZI and further clinical development of its pipeline candidates. The offering was led by notable healthcare investors, reflecting confidence in Coherus's strategic direction.
Read more →CHRS▼ -19.9%on this newsshared move
Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock
Coherus Oncology, Inc. has announced the pricing of a public offering consisting of 28,600,000 shares of its common stock at a price of $1.75 per share, aiming to raise approximately $50.1 million. The company plans to use the net proceeds to support the commercialization of its oncology drug LOQTORZI, advance clinical development of other candidates, and for general corporate purposes. The offering is expected to close on or about February 17, 2026, pending customary closing conditions. Coherus' recent activities reflect its strategy to enhance its oncology pipeline and drive future growth.
Read more →CHRSCoherus Oncology, Inc. Announces Proposed Public Offering of Common Stock
Coherus Oncology, Inc. has announced a proposed underwritten public offering of its common stock to bolster the commercialization of its PD-1 inhibitor, LOQTORZI, among other uses. The offering includes an option for underwriters to purchase additional shares, and will be guided by TD Cowen, Guggenheim Securities, and Oppenheimer & Co. The company stresses that the offering is subject to market conditions and does not guarantee completion or specific terms.
Read more →CHRS▼ -5.6%on this news· ran to +17% by day 3
Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference
Coherus Oncology, Inc. (NASDAQ: CHRS) will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, at 10:30 a.m. Pacific Time. The event will feature a presentation by senior management and will be accessible via a webcast. Coherus specializes in oncology, offering an approved PD-1 inhibitor and developing additional candidates for various cancer indications. This initiative highlights the company's strategic efforts to increase its market presence and bolster its clinical pipeline.
Read more →CHRS▲ +5.1%on this newsshared move
Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114)
Coherus Oncology announced the publication of research on its investigational antibody, tagmokitug, in Molecular Cancer Therapeutics. The study highlights its high selectivity and binding affinity for CCR8, demonstrating significant potential in targeting solid tumors. The findings support ongoing clinical trials evaluating tagmokitug's effectiveness in combination with toripalimab.
Read more →CHRSxA9;2026 Coherus Oncology, Inc. Coherus Oncology Value Proposition Shareholder Value Creation Focused on Drugs, Data and Deals 1 DRUGS DATA DEALS Tagmokitug anti-CCR8 cytolytic antibody Casdozokitug IL-27 antagonist Comm
Coherus Oncology, Inc. has reported promising preliminary financial data for the fourth quarter and full year of 2025. The company anticipated strong demand for its drug LOQTORZI, with projections indicating revenues could reach between $150-200 million by 2028. This revenue growth is supported by a projected quarter-over-quarter increase of 10-15% due to ongoing commercial efforts. The financial figures, however, are preliminary and subject to change as they have not yet been audited.
Read more →CHRS▲ +6.7%on this news· ran to +19% by day 3
Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma
Coherus Oncology has announced promising six-year follow-up results from its Phase 3 JUPITER-02 trial, indicating that the combination of LOQTORZI and chemotherapy significantly improves median overall survival in patients with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). The study reports a median survival of 64.8 months for those receiving the combination therapy compared to 33.7 months for chemotherapy alone. These findings stress the need for integrating LOQTORZI as a first-line treatment option, suggesting it may transform patient outcomes in this aggressive cancer setting.
Read more →CHRS▼ -7.4%on this news
Cautionary Statement Regarding Forward-Looking Statements Certain matters discussed herein contain forward-looking statements. Any statements contained herein that are not statements of historical facts contained in this
Coherus Oncology has issued a cautionary statement regarding forward-looking statements in its latest annual report. The company recently completed the divestiture of its UDENYCA Business, marking a significant strategic shift away from biosimilars to concentrate on its immuno-oncology candidate, LOQTORZI. This transition is expected to focus on expanding LOQTORZI's sales and exploring new indications. The firm is also set to receive additional payments contingent on future net sales of UDENYCA, indicating potential for further revenue.
Read more →CHRS▼ -10.1%on this news
Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody
Coherus Oncology presented new data on CHS-114 at the SITC meeting, highlighting its ability to selectively deplete CCR8+ Tregs and enhance CD8 T cell presence in tumors. The Phase 1b trial shows promising early antitumor activity, particularly in combination with toripalimab. The safety profile remains manageable, supporting further development of CHS-114 in advanced solid tumors.
Read more →CHRS▼ -10.1%on this newsshared move
Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update
Coherus Oncology reported its Q3 2025 financial results, highlighting a 12% revenue increase for LOQTORZI and the expansion of its CHS-114 clinical program to include colorectal cancer. The company maintains a strong cash position of $191.7 million. Despite a net loss of $44.5 million, Coherus is optimistic about upcoming data readouts in 2026.
Read more →CHRSArvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer
Coherus Oncology has appointed Arvind Sood as Chief Strategy and Corporate Affairs Officer. Sood will oversee corporate development and investor relations, focusing on the company's innovative cancer therapies. His extensive background in biotechnology is expected to strengthen Coherus' strategic initiatives and investor engagement as the company advances its clinical pipeline.
Read more →CHRSCoherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025
Coherus Oncology, Inc. has announced that it will release its third quarter 2025 financial results on November 6, 2025, after market close. Following the release, the management team will hold a conference call and webcast to discuss the results and provide a general business update. The company highlights its pipeline, including innovative therapies such as LOQTORZI and other cancer-focused candidates.
Read more →CHRSCoherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Coherus Oncology announced a poster presentation for CHS-114 at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) scheduled for November 5-9, 2025. The presentation will focus on the monoclonal antibody's ability to selectively deplete Tregs and enhance immune response in patients with advanced solid tumors. Additionally, CHS-114 will be discussed in a related webinar series.
Read more →CHRSCoherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update - LOQTORZI net revenue was $10.0 million, a 36% increase over Q1 2025 - - Data readouts for CHS-114 and casdozokitug on track fo
Coherus Oncology reported its second quarter 2025 financial results, revealing a 36% increase in LOQTORZI net revenue to $10 million compared to Q1 2025. The company has maintained a solid cash position of $238 million and continues to advance its pipeline candidates, CHS-114 and casdozokitug, with important data readouts anticipated in 2026. Despite these positive developments, Coherus reported a net loss of $44.9 million for the quarter, highlighting ongoing financial challenges.
Read more →CHRSCoherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025
Coherus Oncology, Inc. is set to release its financial results for the second quarter of 2025 on August 7, 2025, after market close. The management team will then host a conference call at 5:00 p.m. EDT to discuss these results as well as provide a business update. The company, which specializes in oncology treatments, has reported growth in sales of its PD-1 inhibitor, LOQTORZI, and is advancing multiple candidates in its pipeline targeting various cancers.
Read more →CHRSCoherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics
Coherus Oncology has officially changed its name from Coherus BioSciences to better reflect its commitment to innovative cancer therapeutics. The company is focusing on developing proprietary immuno-oncology medicines, including the FDA-approved LOQTORZI. Coherus aims to advance combination therapies that target immune resistance in various cancers, supported by a strong advisory board.
Read more →CHRSCoherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI (toripalimab-tpzi)
Coherus BioSciences has announced a clinical collaboration with STORM Therapeutics to assess the combination of STC-15 with LOQTORZI in treating various cancers including NSCLC and melanoma. The collaboration includes a Phase 1b/2 study, currently underway, designed to evaluate the safety and efficacy of the treatment combination. Coherus will supply LOQTORZI while STORM sponsors the trial. This collaboration highlights Coherus' strategy to extend the applications of LOQTORZI beyond its current indications.
Read more →CHRS▲ +5.3%on this news· ran to -21% by day 3
Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update - Strategic transformation to innovative oncology completed in Q2 2025 - - Positive CHS-114 (anti-CCR8 antibody) Phase 1b dose
Coherus BioSciences reported its financial results for the first quarter of 2025, showcasing a significant transformation towards an oncology-focused portfolio. The company highlighted positive data from the Phase 1b study of CHS-114, an anti-CCR8 antibody, and ongoing enrollment in trials involving casdozokitug and toripalimab. Despite achieving a higher revenue from continuing operations, Coherus faced a net loss. The strategic divestiture of the UDENYCA product line is expected to bolster its focus on innovative treatment options.
Read more →CHRS▼ -7.3%on this news
Coherus to Report First Quarter 2025 Financial Results on May 12, 2025
Coherus BioSciences announced it will release its financial results for the first quarter of 2025 on May 12, 2025, after market close. The company's management will host a conference call at 5:00 p.m. EDT on the same day to discuss these results and provide a general business update. The press release and other relevant materials will be available on their investor website prior to the call. Coherus continues to develop its oncology pipeline, including new indications for its PD-1 inhibitor, LOQTORZI.
Read more →CHRSCoherus to Participate in Upcoming Investor Conferences
Coherus BioSciences, Inc. announced its participation in several upcoming investor conferences, including the Citizens Life Science Conference and the HCW BioConnect @ Nasdaq NYC 2025. During these events, the company will showcase its commercial-stage oncology products, particularly the PD-1 inhibitor LOQTORZI, as well as its promising pipeline of clinical candidates targeting various cancers. The webcasts will be available on the Coherus website, providing investors with access to company presentations and opportunities for one-on-one meetings.
Read more →CHRSCoherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025
Coherus BioSciences presented promising early data for CHS-114 at the 2025 AACR Annual Meeting. The Phase 1 dose expansion study highlighted a confirmed partial response in a heavily pretreated PD-1 refractory patient, suggesting potential efficacy when combined with toripalimab in HNSCC. Importantly, CHS-114 exhibited a significant increase in CD8+ T cells and a manageable safety profile. The ongoing study supports continued exploration of CHS-114's application in HNSCC and gastric cancer, with expectations for further results in 2026.
Read more →CHRS▲ +16.6%on this news· ran to +34% by day 3
Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA Franchise - $250 million post-close cash balance extends cash runway over two years into 2027, funding pipeline development through key da
Coherus BioSciences has successfully completed the divestiture of its UDENYCA franchise to Intas Pharmaceuticals, resulting in a significant cash balance of $250 million. This strategic move allows Coherus to concentrate on its innovative oncology programs and its promising pipeline of mid-stage candidates. Following the transaction, Coherus aims to maximize revenues from its PD-1 inhibitor LOQTORZI and advance its other immuno-oncology candidates. The deal includes an upfront payment of $483.4 million and potential milestone payments totaling up to $75 million, contingent on sales performance.
Read more →CHRSCoherus Announces Repurchase of Approximately $170 Million of Convertible Notes - Remaining $60 Million of outstanding convertible notes to be repurchased post-close of pending UDENYCA divestiture
Coherus BioSciences, Inc. has announced the repurchase of approximately $170 million in convertible notes as part of a strategy to strengthen its financial position. This move is contingent on the successful closing of its planned UDENYCA divestiture. Following the repurchase, the company will retain about $60 million in convertible notes, which it aims to repurchase after completing the divestiture. Furthermore, the company has received majority consent from the holders of these notes for necessary amendments to facilitate the transaction.
Read more →CHRSCoherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting
Coherus BioSciences has announced that it will present interim data from its Phase 1 clinical trial of CHS-114 at the 2025 AACR Annual Meeting. This trial evaluates CHS-114 as a solo treatment and in combination with toripalimab for patients with advanced head and neck squamous cell carcinoma. The study aims to optimize the dosing of CHS-114 and assess its safety and antitumor activity. The upcoming poster presentation is part of the company's efforts to advance its innovative oncology pipeline.
Read more →CHRSCoherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update - Annual net revenue increased 4% to $267.0 million in 2024, despite significant divestitures - - UDENYCA net reve
Coherus BioSciences reported a 4% increase in annual net revenue for 2024, totaling $267 million. Notably, UDENYCA's net revenue rose significantly by 62% year-over-year. The company plans to divest UDENYCA, expecting to close the transaction by early second quarter 2025, which will bolster its cash position to approximately $250 million. However, the company also faces challenges, including a significant net loss in the fourth quarter and a planned reduction in workforce by 30% following the divestiture of its biosimilar products.
Read more →CHRS▼ -9.5%on this news
Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025
Coherus BioSciences, Inc. has announced that it will release its fourth quarter and full year 2024 financial results after market close on March 10, 2025. A conference call and webcast will follow at 5:00 p.m. ET to discuss these results. Coherus is known for its immunotherapy products and is actively developing a pipeline of antibody candidates targeting cancer treatments. The press release and related materials will be available on their investor website prior to the call.
Read more →CHRS▲ +7.5%on this news
Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference
Coherus BioSciences has announced that its senior management will participate in a fireside chat at the 45th Annual TD Cowen Health Care Conference. The event is scheduled for March 4, 2025, at 11:50 a.m. Eastern time. A live audio webcast will be available through the company's investor website, along with a replay for approximately 90 days. This participation highlights Coherus' commitment to investor relations and communication.
Read more →CHRSCoherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
Coherus BioSciences presented final Phase 2 clinical trial data for casdozokitug, showing a complete response rate increase to 17.2% in patients with unresectable metastatic hepatocellular carcinoma. The trial demonstrated an overall response rate of 38%, indicating both improved efficacy and a favorable safety profile. The data supports further evaluation of casdozokitug in combination with other therapies. A new randomized Phase 2 trial evaluating casdozokitug alongside toripalimab and bevacizumab has opened for enrollment.
Read more →CHRSPreliminary Revenues and Cash ©2025 Coherus BioSciences 39 2024 Total Year Expected Net Revenues $255M- $260M Cash, Cash Equivalents & Investments Q4 expected net revenues $49M-$54M OBI and strong pricing continue t
Coherus BioSciences is anticipating total net revenues between $255 million and $260 million for the year 2024, with quarterly revenues expected to range from $49 million to $54 million in Q4. The release of the full financial results is scheduled for March 2025. The company plans to divest its UDENYCA Franchise and repay $230 million in convertible notes due in 2026. However, these transactions are contingent upon several conditions, including shareholder approval and regulatory clearances.
Read more →CHRSCoherus Management to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Coherus BioSciences, Inc. has announced that its senior management will present at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for January 13, 2025, at 5:15 p.m. Pacific Time. Interested parties can access the presentation and Q&A session via a webcast, which will also be available for replay until February 10, 2025.
Read more →CHRS▼ -8.2%on this news
Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
Coherus BioSciences announced the presentation of final Phase 2 data on casdozokitug, an IL-27 antagonist, at the upcoming ASCO-GI 2025 conference. The trial evaluates the combination of casdozokitug, toripalimab, and bevacizumab in patients with unresectable HCC. Early data indicated encouraging responses when casdozo was added to existing treatment regimens. The new randomized Phase 2 study aims to assess the safety and efficacy of this triplet combination treatment for HCC.
Read more →CHRS▲ +24.8%on this news
Coherus Announces Agreement to Divest UDENYCA Franchise for up to $558 million to Intas Pharmaceuticals Ltd. - Coherus to focus exclusively on innovative immuno-oncology programs that include LOQTORZI , an FDA approved,
Coherus BioSciences has announced a divestiture agreement with Intas Pharmaceuticals for its UDENYCA franchise, valued at up to $558 million. The agreement includes an upfront payment of $483.4 million and potential milestone payments. The proceeds are intended to enhance Coherus' focus on its immuno-oncology pipeline, particularly the development of LOQTORZI, an FDA-approved PD-1 inhibitor. The transaction is expected to close by the end of Q1 2025, subject to shareholder approval and regulatory conditions.
Read more →CHRSCoherus Management to Participate in the 2024 Citi Global Healthcare Conference
Coherus BioSciences, Inc. has announced that its senior management will participate in the upcoming 2024 Citi Global Healthcare Conference. Dr. Theresa LaVallee, the Chief Development Officer, will be part of the panel discussing Novel Mechanisms in Oncology on December 3, 2024. This event will be webcasted for accessible viewing through the company's website.
Read more →CHRSCoherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update - Net revenue of $70.8 million in Q3 2024 driven by 30% increase in UDENYCA net revenue, quarter-over-quarter- - UDENYCA label
Coherus BioSciences has reported a strong financial performance for Q3 2024, with net revenue of $70.8 million, driven primarily by a 30% increase in UDENYCA sales. The launch of LOQTORZI is also showing promising results, with a 50% revenue increase quarter-over-quarter. The company's focus on advanced immuno-oncology projects is progressing towards proof-of-concept stages. Despite having a net loss of $10.8 million, the company's financial health shows improvement compared to the same quarter last year.
Read more →CHRSCoherus to Report Third Quarter 2024 Financial Results on November 6, 2024
Coherus BioSciences, Inc. has announced that it will release its third quarter 2024 financial results after the market closes on November 6, 2024. A conference call and webcast will follow at 5:00 p.m. ET the same day, where management will discuss these results and provide a general business update. Investors can access the materials and a live webcast through the company's investor relations website.
Read more →CHRSCoherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update - Net revenue of $65.0 million in Q2 2024 - - CHS-114 Phase 1 Study Recruitment Continues into Expansion Cohorts in Head and
Coherus BioSciences announced its financial results for Q2 2024, revealing a net revenue of $65.0 million, driven by strong sales of UDENYCA and LOQTORZI. The company continued its recruitment for the Phase 1 study of CHS-114 in head and neck cancer, emphasizing its focus on immuno-oncology. Bryan McMichael was appointed as Chief Financial Officer, which is expected to bolster the company’s financial strategy. Despite a net loss of $12.9 million for the quarter, the results showed notable improvement compared to the previous year.
Read more →CHRS▼ -7.1%on this news
Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024
Coherus BioSciences, Inc. has announced that it will release its second quarter 2024 financial results after market close on August 8, 2024. The management team will conduct a conference call and webcast at 5:00 p.m. EDT to discuss these results and provide an update on the business. Interested parties can access the conference call by pre-registering for dial-in details, and a replay of the webcast will be available on their investor relations website.
Read more →CHRSCoherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction - Transaction aligns with Coherus' strategic focus on oncology
Coherus BioSciences announced the divestiture of YUSIMRY (adalimumab-aqvh) for $40 million in cash to Hong Kong King-Friend Industrial Co. Ltd. The transaction, closed on June 26, 2024, aligns with Coherus' strategic shift towards oncology, enhancing its financial position for future growth. Coherus plans to focus resources on its ongoing oncology projects, including several innovative immunotherapy candidates.
Read more →CHRSCoherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors
Coherus BioSciences has appointed Rita Karachun, CPA, CGMA, to its Board of Directors, effective May 31, 2024. Karachun, who previously served as Senior Vice President and Global Controller for Merck, brings nearly four decades of experience in finance and operational management. Her expertise is expected to be instrumental as Coherus continues to develop innovative cancer therapies. The company is focused on transforming its operations and advancing its immuno-oncology pipeline.
Read more →CHRSCoherus Management to Present at the 2024 Jefferies Global Healthcare Conference
Coherus BioSciences has announced that its senior management will present at the 2024 Jefferies Global Healthcare Conference on June 6, 2024. The presentation is scheduled for 8:30 a.m. EDT and will be accessible via a webcast, which can be replayed until July 7, 2024. This event will provide an opportunity for Coherus to update investors on its progress and strategic initiatives.
Read more →CHRSCoherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA
Coherus BioSciences has announced that its senior management will present at the upcoming TD Cowen 5th Annual Oncology Innovation Virtual Summit on May 29, 2024. The presentation will focus on insights for ASCO & EHA and will be accessible via a webcast. The event underscores Coherus' involvement in oncology and its ongoing commitment to sharing information with the investment community.
Read more →CHRSCoherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Coherus BioSciences presented preliminary results from a Phase I dose escalation study of its anti-CCR8 antibody CHS-114 at the 2024 ASCO Annual Meeting. The results indicate that CHS-114 has an acceptable safety profile with no dose-limiting toxicities observed in heavily pretreated patients. The study demonstrated selective depletion of CCR8+ regulatory T cells, which could enhance anti-tumor responses when combined with existing immunotherapies like toripalimab. However, despite encouraging data, no objective responses were noted in the evaluable patients thus far.
Read more →CHRSCoherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update - Net revenue of $77.1 million in Q1 2024 - - CRI and ENB Therapeutics development partnership for toripalimab in ovarian canc
Coherus BioSciences has reported a strong financial performance for Q1 2024, generating a net revenue of $77.1 million, significantly up from the same quarter last year. The company also announced a substantial gain from the sale of its ophthalmology franchise, further strengthening its financial position. Additionally, Coherus has formed a development partnership with CRI and ENB Therapeutics aimed at advancing toripalimab for ovarian cancer treatment. Despite these accomplishments, the company faces challenges, including rising administrative costs and ongoing regulatory uncertainties.
Read more →CHRSCoherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan
Coherus BioSciences has announced the full repayment of its $75 million term loan to Pharmakon Advisors, facilitated through a new financing agreement with Barings. This transaction halves the company’s term loan debt and extends the loan’s maturity date to May 2029, aligning better with its development timeline. The financing includes $37.5 million from royalty monetization based on future sales of its products LOQTORZI and UDENYCA, further strengthening its capital structure.
Read more →CHRSCoherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer
Coherus BioSciences has announced a collaboration with the Cancer Research Institute for a clinical study exploring the combination of LOQTORZI (toripalimab-tpzi) and ENB-003 to treat platinum-resistant high-grade serous ovarian cancer. This study utilizes the iPROC platform, which allows for the evaluation of various immunotherapy combinations under a single protocol. The collaboration aims to leverage the strengths of both companies to enhance treatment options for patients facing difficult-to-treat cancers. LOQTORZI has shown efficacy in previous studies, making the combination promising for enhancing patient outcomes.
Read more →CHRS▲ +5.1%on this news
Coherus to Report First Quarter 2024 Financial Results on May 9, 2024
Coherus BioSciences, Inc. has announced that it will report its financial results for the first quarter of 2024 after market close on May 9, 2024. A conference call and webcast will take place starting at 5:00 p.m. EDT, where management will discuss the financial results and provide a business update. An audio replay of the webcast will be made available on the company’s investor relations website following the call.
Read more →CHRS▼ -7.3%on this news
Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Coherus BioSciences announced that it will present clinical data for its anti-CCR8 antibody, CHS-114, at the 2024 ASCO Annual Meeting. This presentation will focus on the preliminary results from a Phase 1, first-in-human, dose escalation study involving patients with advanced solid tumors. CHS-114 has shown potential in selectively depleting CCR8+ regulatory T cells in tumor environments while sparing normal tissue. The results may provide insights into its effectiveness and safety profile in immunotherapy.
Read more →CHRSCoherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting
Coherus BioSciences presented preclinical data for its novel anti-ILT4 monoclonal antibody, CHS-1000, at the 2024 AACR Annual Meeting. The data suggest that CHS-1000 selectively binds to ILT4, reversing immunosuppressive functions within the tumor microenvironment and enhancing immune responses. The company plans to submit an IND application for CHS-1000 in Q2 2024 and is optimistic about advancing the candidate into clinical trials, both as a standalone treatment and in combination with existing therapies.
Read more →CHRSCoherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
Coherus BioSciences has reported its financial results for Q4 and FY 2023, showing a significant net revenue increase to $257.2 million. The company successfully launched products such as UDENYCA ONBODY and LOQTORZI, and has initiated a strategic divestiture of its ophthalmology franchise to focus on oncology. However, the company is also implementing a 30% workforce reduction to optimize costs amid restructured milestone payments related to its product portfolio. Additional product line developments and clinical collaborations are underway to enhance growth in the oncology market.
Read more →CHRSCoherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update - Net revenue of $91.5 million in the fourth quarter and $257.2 million in FY 2023 - - UDENYCA net sales o
Coherus BioSciences reported its financial results for the fourth quarter and full year 2023, highlighting a substantial net revenue increase driven by product launches. The company achieved a net revenue of $91.5 million in Q4 and $257.2 million for FY 2023, up from the previous year. However, Coherus also reported a net loss of $79.7 million in Q4, an increase from 2022, and announced a workforce reduction of 30% as part of a corporate restructuring to sharpen its focus on oncology. The company remains optimistic about its immuno-oncology pipeline and ongoing product launches planned for 2024.
Read more →CHRSCoherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024
Coherus BioSciences, Inc. has announced that it will release its fourth quarter and full-year financial results for 2023 on March 13, 2024, after market close. Following the release, the management team will host a conference call at 5:00 PM ET to discuss the results and provide a business update. Participants are encouraged to pre-register for the call to obtain dial-in information. A webcast of the call will also be available on the company's investor website both live and in an archived format.
Read more →CHRS▼ -5.8%on this newsshared move
Coherus Completes Divestiture of Ophthalmology Franchise - Upfront cash payment of $170 million strengthens capital structure - - Transaction solidifies Coherus' strategic focus in oncology
Coherus BioSciences has completed the sale of its ophthalmology franchise, including the CIMERLI biologics license, to Sandoz for $170 million. This move enables Coherus to sharpen its focus on oncology, supporting the advancement of its immuno-oncology pipeline. The proceeds from the sale will be used to reduce debt, lower interest costs, and decrease overhead, which are crucial for the company's sustained growth in oncology. The transaction is part of Coherus' strategic plan to improve its operations and financial position.
Read more →CHRSCoherus BioSciences Announces New Employment Inducement Grants
Coherus BioSciences, Inc. announced the granting of stock options totaling 170,000 shares to three new employees, effective February 20, 2024. This move aims to incentivize talent acquisition and was done under the Company's 2016 Employment Commencement Incentive Plan. Notably, one Executive Vice President received a significant portion of the options, reflecting the company's strategic hiring approach.
Read more →CHRSCoherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv
Coherus BioSciences has launched the UDENYCA ONBODY, an innovative on-body injector for its pegfilgrastim biosimilar that allows for a five-minute administration time. The device aims to enhance the treatment experience for cancer patients by offering features that maximize safety and comfort. Provider feedback has been positive, noting the advantages of being able to administer treatment outside traditional care settings. The launch further expands the UDENYCA franchise, which now includes multiple administration options for patient convenience.
Read more →CHRSCoherus Amends Term Loan Agreement with Pharmakon Advisors, LP - Estimated balance of $75 million upon $175 million paydown of principal projected in Q2 2024 - - Revenue covenant reduced to $125 million - - Term loan ann
Coherus BioSciences has amended its term loan agreement with Pharmakon Advisors, LP, which includes a significant prepayment of $175 million on its existing $250 million loan. This strategic move, following the divestiture of its ophthalmology franchise, is expected to lower its estimated loan balance to $75 million and reduce its annual interest expenses by around 70%. The company aims to bolster its financial health and support growth in its oncology-focused business, enhancing its position in the market.
Read more →CHRS▲ +5.7%on this news
Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal Transaction aligns to Coherus strategic focus on oncology Conference call Monday
Coherus BioSciences has entered a $170 million all-cash agreement with Sandoz to divest its ophthalmology franchise, including the CIMERLI product. This strategic shift aims to focus resources on its core oncology business and reduce debt. The deal comes with additional considerations for product inventory and is expected to close in the first half of 2024, pending regulatory approvals. Coherus anticipates that this divestiture will enhance its operational efficiency and support its growing oncology pipeline.
Read more →CHRSCoherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium
Coherus BioSciences presented promising Phase 2 clinical data for casdozokitug, an IL-27-targeted antibody, at the 2024 ASCO GI Cancers Symposium. The trial showed a 38% objective response rate in patients with unresectable hepatocellular carcinoma (uHCC), which included three complete responses. The safety profile was deemed acceptable, supporting ongoing evaluation of casdozokitug in combination therapies. This early data suggests that casdozokitug could contribute significantly to treatment advancements in liver cancer.
Read more →CHRSCoherus BioSciences Management to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Coherus BioSciences, Inc. will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024. The presentation is scheduled for 9:45 a.m. Pacific Time, and will include a Q&A session accessible via a Webcast. This event is an opportunity for Coherus to showcase its developments and engage with potential investors. The webcast will remain available for replay until February 9, 2024.
Read more →CHRS▼ -5.7%on this newsshared move
Coherus Announces U.S. Launch of LOQTORZI™
Coherus BioSciences has launched LOQTORZI™, the first and only FDA-approved treatment for nasopharyngeal carcinoma (NPC) available through select specialty distributors in the U.S. This next-generation anti-PD-1 monoclonal antibody is indicated for use in combination with chemotherapy or as a monotherapy for patients who have progressed on previous treatments. Clinical studies show LOQTORZI significantly enhances both progression-free survival and overall survival rates in affected patients, providing new hope for a patient population with limited prior treatment options. The launch signifies Coherus's emergence as a commercial-stage immuno-oncology company focused on addressing the unmet needs in treating rare cancers.
Read more →CHRS▲ +7.9%on this news· ran to +65% by day 3
Coherus Announces FDA Approval of UDENYCA ONBODY™, a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv
Coherus BioSciences has received FDA approval for UDENYCA ONBODY™, an innovative on-body injector for pegfilgrastim, designed to deliver medication in just five minutes. This proprietary device prioritizes patient safety and comfort with an automatic retractable needle mechanism. Expected to be available commercially in the first quarter of 2024, UDENYCA ONBODY adds to the existing administration options for patients, addressing significant market demand. Despite its advantages, the device's potential for failure and associated risks require careful monitoring during use.
Read more →CHRSCoherus Announces Updated NCCN Clinical Practice Guidelines Positioning LOQTORZI™ (toripalimab-tpzi) as Preferred Category 1 Regimen for First-Line Treatment of Cancer of the Nasopharynx
Coherus BioSciences announced that LOQTORZI (toripalimab-tpzi) has been included in the updated NCCN guidelines as the preferred Category 1 treatment for metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC) when used with chemotherapy. LOQTORZI is the first FDA-approved therapy for this type of cancer, and its inclusion in these guidelines signifies a new standard of care. The recommendations are based on clinical studies that show significant improvement in patient survival and disease progression outcomes.
Read more →CHRSCoherus BioSciences Announces CFO Transition Plans
Coherus BioSciences has announced the resignation of CFO McDavid Stilwell, effective December 31, 2023, to pursue other opportunities. While the company has expressed gratitude for Stilwell's contributions towards its product portfolio growth, it aims to promptly appoint an interim Chief Financial Officer. Analysts indicate that this transition might bring temporary uncertainty; however, Coherus remains focused on upcoming product launches that could enhance shareholder value.
Read more →CHRSCoherus Presents Phase 1/2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2023 ESMO Immuno-Oncology Congress
Coherus BioSciences presented data from its Phase 1b/2 trial of casdozokitug, an IL-27-targeting antibody, at the 2023 ESMO Immuno-Oncology Congress. The trial showed promising anti-tumor activity in squamous NSCLC patients, with two of nine experiencing confirmed partial responses. Casdozokitug demonstrated acceptable safety and efficacy, supporting its continued evaluation alongside other PD-1 inhibitors. The company anticipates additional data from ongoing studies in the coming months.
Read more →CHRS▲ +8.8%on this news
Coherus and Junshi Biosciences Announce Publication of Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Trial Evaluating LOQTORZI™ (toripalimab-tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical Association
Coherus BioSciences and Junshi Biosciences published the final overall survival results from the JUPITER-02 study in JAMA, showcasing LOQTORZI's effectiveness. The study indicated a 37% reduction in mortality risk for patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) using LOQTORZI plus chemotherapy. FDA approval for this treatment has been secured, with plans for launch in January 2024. LOQTORZI is set to establish a new standard of care for NPC treatment in the U.S.
Read more →CHRSCoherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights - Net revenue rose 27% from prior quarter to $74.6 million - - CIMERLI net sales increased 50% to $40 million compared to prior qua
Coherus BioSciences reported its third quarter 2023 financial results, highlighting a 27% increase in net revenue to $74.6 million, driven primarily by strong sales of CIMERLI, which surged by 50%. The company also announced the approval of LOQTORZI, intending to launch it in the first quarter of 2024. However, Coherus reduced its revenue guidance for the year, expecting a range of $250 to $260 million due to delays in product launches. Additionally, while R&D and SG&A expenses have decreased, the company still reported a significant net loss during the quarter, signaling challenges ahead.
Read more →CHRS▲ +8.7%on this news· ran to -39% by day 3shared move
Coherus BioSciences to Participate at Upcoming November Investor Conferences
Coherus BioSciences, Inc. (Nasdaq: CHRS) has announced its participation in several investor conferences throughout November 2023. The company will engage in one-on-one meetings at the Truist Securities BioPharma Symposium in New York City on November 8. Additionally, Coherus will present a fireside chat at the UBS Biopharma Conference in Miami on November 9, as well as at the Evercore ISI HealthCONx Conference held from November 28-30 in Miami. Webcasts of these presentations will be made available on their investor relations page.
Read more →CHRS▲ +8.7%on this news· ran to -39% by day 3shared move
Coherus Presents Data from Next-generation Immuno-oncology Programs at 38th Annual Meeting of Society for Immunotherapy of Cancer (SITC)
Coherus BioSciences presented data at the SITC annual meeting that highlighted advancements in its next-generation immuno-oncology programs. The company showcased the anti-IL-27 antibody casdozokitug, the anti-CCR8 antibody CHS-114, and the anti-PD-1 antibody LOQTORZI™, each exhibiting unique mechanisms and potential efficacy against various cancer types. Key findings indicated improved tumor responses and biomarkers for effective treatment. The research indicates promising avenues for enhancing cancer therapy outcomes.
Read more →CHRS▲ +14%on this news· ran to +27% by day 1
Coherus BioSciences to Report Third Quarter 2023 Financial Results on November 6, 2023
Coherus BioSciences has announced that it will release its third quarter 2023 financial results on November 6, 2023, after market close. The management team will host a conference call and webcast at 5:00 p.m. ET the same day to discuss the results and provide a general business update. Investors can access the call by pre-registering, and a press release with the financial results will be available prior to the call.
Read more →CHRSCoherus and Junshi Biosciences Announce FDA Approval of LOQTORZI (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) - LOQTORZI is the first and only FDA-approved treat
Coherus BioSciences and Junshi Biosciences have received FDA approval for LOQTORZI (toripalimab-tpzi), the first and only treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC). The approval allows for use in combination with chemotherapy or as monotherapy for patients with disease progression after platinum-containing chemotherapy. This therapy significantly improved progression-free survival and overall survival in clinical trials. LOQTORZI is expected to be available in the U.S. by Q1 2024, expanding treatment options for NPC patients.
Read more →CHRSCoherus Announces Toripalimab Data at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Coherus BioSciences presented new data on its anti-PD-1 monoclonal antibody, toripalimab, at the AACR-NCI-EORTC International Conference. The results demonstrated significantly higher T cell activation and overall survival improvements when toripalimab was used in conjunction with chemotherapy, independent of PD-L1 expression levels. The company is currently awaiting FDA review for a biologics license application concerning toripalimab's use for treating recurrent or metastatic nasopharyngeal carcinoma. These findings position toripalimab as a potentially more effective treatment option compared to existing therapies.
Read more →CHRS▲ +9.5%on this news· ran to +20% by day 3
Coherus Announces Resubmission of Biologics License Application (BLA) Supplement for UDENYCA ONBODY™
Coherus BioSciences has resubmitted its Biologics License Application Supplement for UDENYCA ONBODY™ to the FDA after resolving inspection findings at a third-party filler. The FDA's Complete Response Letter did not highlight any issues with clinical efficacy, safety, or other critical aspects of the product. Coherus expresses optimism about a timely review and potential approval later this year, underscoring its commitment to delivering this treatment to cancer patients.
Read more →CHRSCoherus Applauds Congressional Designation of September 30th as Rare Cancer Day
Coherus BioSciences has expressed support for the Congressional designation of September 30th as Rare Cancer Day, which aims to raise awareness for rare cancers such as nasopharyngeal carcinoma (NPC). This bipartisan resolution aims to highlight the challenges faced by patients with rare cancers, who often have limited treatment options. Coherus emphasizes the importance of awareness initiatives for improving early diagnosis and treatment outcomes for underserved populations affected by these conditions. The company is actively engaged in developing new immunotherapy treatments for these rare cancers.
Read more →CHRSCoherus Announces Three Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Coherus BioSciences announced the presentation of three abstracts related to its immuno-oncology pipeline at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in November 2023. The presentations will focus on key aspects of their lead candidates, including toripalimab, an anti-PD-1 antibody currently under FDA review for nasopharyngeal carcinoma. This event highlights Coherus's ongoing commitment to developing cutting-edge therapies in cancer treatment, especially following their recent acquisition of Surface Oncology, which has broadened their pipeline significantly.
Read more →CHRSCoherus Completes Surface Oncology Acquisition
Coherus BioSciences has successfully completed its acquisition of Surface Oncology, significantly enhancing its immuno-oncology pipeline. This acquisition introduces new clinical-stage assets, including casdozokitug and CHS-114, which may provide improved treatment options for cancer patients. Coherus aims to leverage these assets to expand toripalimab's use into larger indications. However, the integration of Surface's operations presents risks, and uncertainties remain regarding regulatory approvals.
Read more →CHRSCoherus Completes Surface Oncology Acquisition - Clinical-stage product candidates, casdozokitug and CHS-114, significantly advance next-generation immuno-oncology portfolio focused on the tumor microenvironment - - I-O
Coherus BioSciences has completed its acquisition of Surface Oncology, which enhances its immuno-oncology pipeline with new clinical-stage assets. The acquired products, including casdozokitug and CHS-114, are aimed at improving cancer treatment by targeting the tumor microenvironment. Coherus is optimistic about expanding the use of its existing drug toripalimab into large indications, addressing significant unmet medical needs. However, the integration process and regulatory approvals present challenges that need to be managed carefully.
Read more →CHRSCoherus BioSciences to Participate at Upcoming September Investor Conferences
Coherus BioSciences, Inc. announced participation in several upcoming investor conferences in September 2023, including the Citi BioPharma Conference and Wells Fargo Healthcare Conference. At these events, senior management will engage with investors through panel discussions and one-on-one meetings. The company aims to enhance its visibility in the biopharma sector. Presentations will be accessible via a live audio webcast on the Coherus investor relations website.
Read more →CHRSCoherus BioSciences Reports Second Quarter 2023 Financial Results and Business Highlights - Net revenue rose 81% from prior quarter to $58.7 million - - CIMERLI net sales quadrupled to $26.7 million compared to prior qua
Coherus BioSciences reported strong financial results for Q2 2023, with an 81% increase in net revenue to $58.7 million. Major contributors to this growth include a significant rise in CIMERLI sales, which quadrupled to $26.7 million. The company also highlighted the planned merger with Surface Oncology, which is expected to enhance its next-generation immuno-oncology product pipeline. Despite the positive revenue growth, Coherus incurred a net loss of $42.9 million during the quarter.
Read more →CHRSCoherus BioSciences to Report Second Quarter 2023 Financial Results on August 02, 2023
Coherus BioSciences, Inc. has announced that it will release its second quarter 2023 financial results on August 2, 2023. The results will be shared after market close, followed by a conference call at 5:00 pm ET to discuss the outcomes and provide a general business update. Stakeholders can pre-register for the call through an online link and access the results via the company's investor relations page.
Read more →CHRSCoherus BioSciences Appoints Dr. Michael Ryan to its Board of Directors
Coherus BioSciences has appointed Dr. Michael Ryan to its Board of Directors to leverage his extensive experience in biopharma commercialization. Dr. Ryan has a notable background with companies such as Bristol Myers Squibb and Amgen, and he aims to support Coherus in launching new products and enhancing patient access to therapies. His appointment is expected to provide valuable insights as the company focuses on its strategic vision in immuno-oncology.
Read more →CHRSCoherus and Superior Biologics Announce National Distribution Agreement for YUSIMRY™
Coherus BioSciences and Superior Biologics announced a national distribution agreement for YUSIMRY, a biosimilar of Humira, priced at $995 per carton. This represents over an 85% discount compared to Humira, aiming to provide patients with high-quality, affordable treatment options. Coherus emphasized their collaboration with Superior Biologics to ensure quality patient care during distribution. However, the treatment comes with warnings regarding serious infections and risks of malignancies. This agreement is seen as a game-changer for both patients and employers facing high specialty drug costs.
Read more →CHRSCoherus Launches YUSIMRY™, a Biosimilar of Humira , at $995 per Carton in U.S.
Coherus BioSciences has launched YUSIMRY, a biosimilar to Humira, in the U.S. at a competitive price of $995 per carton, significantly lower than Humira's price. This aims to improve access for patients with serious autoimmune diseases. By investing in large-scale manufacturing, Coherus positions itself as a low-cost producer. Despite the benefits, there are important safety concerns, including increased risks for serious infections and malignancies associated with the treatment. Healthcare providers will need to monitor patients closely during their therapy.
Read more →CHRS▼ -23.4%on this news
Coherus to Acquire Surface Oncology
Coherus BioSciences, Inc. has announced a definitive merger agreement to acquire Surface Oncology, which will enhance Coherus' immuno-oncology pipeline by adding two clinical-stage assets targeting tumor microenvironments. The acquisition, valued at up to $65 million, is expected to close in the third quarter of 2023 and has received unanimous approval from both companies' boards. Coherus is also anticipating significant revenue growth and aims to launch its new drug toripalimab soon after receiving FDA approval.
Read more →CHRS▼ -23.4%on this news
Coherus to Acquire Surface Oncology Surface acquisition and potential toripalimab approval will transform Coherus into an I-O company with multiple next-generation immunotherapies in clinical development funded by growin
Coherus BioSciences has announced its definitive merger agreement to acquire Surface Oncology, a move expected to enhance its immuno-oncology (I-O) pipeline. The acquisition, valued at up to $65 million, will add two promising clinical-stage assets, SRF388 and SRF114, to Coherus's portfolio. As a result, Coherus is positioned to drive significant revenue growth and position itself as a formidable player in the I-O space. However, the deal includes workforce reductions at Surface, indicating some operational risks ahead.
Read more →CHRS▲ +11.9%on this news
Coherus Announces Positive Final Overall Survival Results of JUPITER-02 Phase 3 Trial Evaluating Toripalimab in Nasopharyngeal Carcinoma
Coherus BioSciences announced positive final overall survival results from the JUPITER-02 Phase 3 trial examining toripalimab in combination with chemotherapy for nasopharyngeal carcinoma (NPC). The study showed a significant reduction in the risk of death and an improvement in overall survival metrics compared to chemotherapy alone. With no current approvals for NPC treatments in the U.S., if toripalimab gains FDA approval, it could establish a new standard of care for patients suffering from this aggressive cancer. The FDA is currently reviewing the Biologics License Application for toripalimab.
Read more →CHRSCoherus Announces Industry-Wide Lowest List Price for Adalimumab Biosimilar YUSIMRY™ (adalimumab-aqvh) Launching in July 2023
Coherus BioSciences, Inc. is launching YUSIMRY™ (adalimumab-aqvh) in July 2023 at a list price of $995 per carton, the lowest price for any adalimumab offering in the U.S., providing an 85% discount compared to Humira. YUSIMRY is a biosimilar TNF blocker intended to treat various autoimmune conditions and aims to meet the needs of patients who face high-cost treatments. The product has been developed with advanced manufacturing techniques to ensure both affordability and reliability in supply.
Read more →CHRSCoherus Announces U.S. Launch of UDENYCA Autoinjector
Coherus BioSciences has launched the UDENYCA autoinjector, a pegfilgrastim product, in the U.S. market. This device allows for quick administration of the drug, designed to assist patients after chemotherapy by reducing the risk of infection. The new autoinjector is seen as a significant advancement for patient convenience, offering both in-office and at-home administration options. Market research indicates positive reception from patients and healthcare providers, emphasizing the product's user-friendly nature and potential impact on access to therapy.
Read more →CHRS▲ +5.9%on this news
Coherus Prices Public Offering of Common Stock
Coherus BioSciences, Inc. has announced the pricing of its public offering of 11,764,706 shares of common stock at $4.25 per share. The net proceeds are expected to be used for general corporate purposes, including manufacturing clinical supplies and investing in complementary businesses. The offering is set to close on or around May 18, 2023, subject to customary conditions. J.P. Morgan and Citigroup serve as co-lead managers for this offering.
Read more →CHRSCoherus Announces Proposed Public Offering of Common Stock
Coherus BioSciences has launched an underwritten public offering to raise $50 million by selling shares of its common stock. The company may also allow underwriters to purchase an additional $7.5 million worth of shares. The funding is intended for corporate purposes, including the production of clinical supplies and potential acquisitions. The offering is subject to market conditions and carries uncertainty regarding completion and terms.
Read more →CHRS▲ +10.3%on this news· ran to -30% by day 3
Coherus BioSciences Reports First Quarter 2023 Financial Results and Business Highlights - UDENYCA autoinjector approved and ready for May 2023 launch - - CIMERLI product-specific Q-code now facilitating electronic reimb
Coherus BioSciences reported its first quarter 2023 financial results, highlighting significant product approvals and launches, including the UDENYCA autoinjector and an activated Q-code for CIMERLI reimbursement. Despite a net loss of $75.7 million, there is optimism surrounding upcoming product launches, especially toripalimab, which could establish a new standard of care. The company anticipates exceeding $275 million in net product revenue for the year, showcasing robust future growth potential amidst current challenges.
Read more →CHRSCoherus BioSciences to Present at Upcoming Investor Conferences in May
Coherus BioSciences, Inc. announced participation in two key investor conferences in May. The first event is the Bank of America Merrill Lynch Global Healthcare 2023 Conference in Las Vegas on May 11, followed by the UBS Global Healthcare Conference at UBS headquarters on May 23. The company will hold a fireside chat at the first conference and 1x1 meetings at the second. An audio webcast of the fireside chat will be available for interested parties.
Read more →CHRS▲ +6.1%on this newsshared move
Coherus BioSciences to Report First Quarter 2023 Financial Results on May 8, 2023
Coherus BioSciences, Inc. announced that it will release its first quarter 2023 financial results after market close on May 8, 2023. Following the release, the company's management team will host a conference call and webcast at 5:00 pm ET to discuss the results and provide a business update. Investors will have the opportunity to access a live webcast and an archived version following the call.
Read more →CHRSCoherus and Junshi Biosciences Announce Toripalimab Studies to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Coherus BioSciences and Junshi Biosciences announced that four pivotal studies on toripalimab will be presented at the 2023 ASCO Annual Meeting. The studies focus on various cancer treatments including nasopharyngeal carcinoma and non-small cell lung cancer. The FDA has granted Breakthrough Therapy designations for toripalimab as a treatment for advanced recurrent or metastatic nasopharyngeal carcinoma. This indicates strong regulatory support for toripalimab as an effective therapeutic option in oncology.
Read more →CHRSCoherus BioSciences Reports Fourth Quarter and Full Year 2022 Results - Net product sales of $45.4 million in the fourth quarter 2022 and $211.0 million in FY 2022 - - FDA is planning the toripalimab manufacturing site i
Coherus BioSciences reported its financial results for Q4 and the full year 2022, highlighting net product sales of $45.4 million for the fourth quarter and $211.0 million for the year. The company anticipates significant growth in 2023, with plans for multiple product launches including toripalimab and a new version of UDENYCA. Despite these optimistic projections, Coherus faced a net loss of $58.9 million in Q4, reflecting ongoing challenges in revenue generation and market competition. The company emphasized a focus on commercial execution and expense management to achieve profitability by 2024.
Read more →CHRSCoherus BioSciences to Present at Upcoming Investor Conferences in March
Coherus BioSciences, Inc. (Nasdaq: CHRS) has announced that its senior management will present at two upcoming investor conferences in March. The presentations are set for the Cowen Health Care Conference on March 7 and the Barclays Global Healthcare Conference on March 14. Audio webcasts of these events will be accessible on the Coherus website, allowing investors to connect and access the content for a period of 30 days afterward.
Read more →CHRSCoherus BioSciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023
Coherus BioSciences, Inc. announced the release date for its fourth quarter and full year 2022 financial results, set for March 6, 2023. Following the release, the management team will host a conference call and webcast to discuss the results and provide a general business update. A replay of the webcast will be made available shortly after the live event.
Read more →CHRSCoherus and Junshi Biosciences Announce Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Clinical Trial Evaluating Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma
Coherus BioSciences and Junshi Biosciences announced positive final results from the JUPITER-02 Phase 3 clinical trial, which evaluated the effectiveness of toripalimab combined with chemotherapy for treating recurrent or metastatic nasopharyngeal carcinoma. The trial demonstrated a statistically significant improvement in overall survival compared to chemotherapy alone. The FDA has previously granted Breakthrough Therapy designation for toripalimab, which positions it as a potentially new standard-of-care treatment for this aggressive type of cancer. These findings will be presented at an upcoming medical meeting.
Read more →CHRSCoherus Granted Permanent, Product-Specific Q-Code for CIMERLI (ranibizumab-eqrn) from the Centers for Medicare and Medicaid Services
Coherus BioSciences announced that the Centers for Medicare and Medicaid Services has granted a permanent, product-specific Q-code for its biosimilar CIMERLI (ranibizumab-eqrn), effective from April 1, 2023. This Q-code will aid in the efficient billing and reimbursement processes for healthcare providers. Coherus anticipates that the utilization of the Q-code will facilitate market conversion, potentially leading to accelerated growth in the coming months. Additionally, Coherus Solutions will provide extensive support to healthcare professionals in managing access and reimbursement for CIMERLI.
Read more →CHRS▼ -6.3%on this news
Coherus Agrees to Acquire Exclusive U.S. Commercial Rights to Eylea Biosimilar FYB203 from Klinge Biopharma
Coherus BioSciences has entered a binding term sheet with Klinge Biopharma to acquire exclusive U.S. commercialization rights for FYB203, a biosimilar candidate to Eylea. The transaction is expected to close in Q1 2023, with a Biologics License Application planned for later this year. CEO Denny Lanfear emphasized the potential of FYB203 to target the lucrative anti-VEGF market, while company executives highlighted their experience in biosimilar commercialization as a key strength for this new product. The deal includes an initial payment and potential milestone payments tied to the product's success.
Read more →CHRS▲ +16%on this newsshared move
Coherus BioSciences Management to Present at the 41st Annual J.P. Morgan Healthcare Conference
Coherus BioSciences, Inc. will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023. The senior management presentation will be available via webcast, allowing broader accessibility. As a commercial-stage biopharmaceutical company, Coherus is focused on developing and commercializing innovative immunotherapies for cancer treatment.
Read more →CHRS▼ -11.8%on this news· ran to +23% by day 3
Coherus and Junshi Biosciences Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
- FDA has been unable to travel to China to conduct the required site inspection resulting in delayed action on the BLA - - Coherus and Junshi Biosciences are actively engaged in ongoing discussions with the FDA to support the inspections and gain approval of toripalimab for pat
Read more →CHRSCoherus BioSciences Reports Third Quarter 2022 Results and Provides Business Update - UDENYCA net sales of $45.4 million in the third quarter 2022 - - CIMERLI launched in the United States on October 3 rd - - Planning un
Coherus BioSciences Reports Third Quarter 2022 Results and Provides Business Update - UDENYCA net sales of $45.4 million in the third quarter 2022 - - CIMERLI launched in the United States on October 3rd - - Planning underway for 2023 commercial launches of toripalimab, YUSIMR
Read more →CHRSCoherus BioSciences to Report Third Quarter 2022 Financial Results on November 8th, 2022
REDWOOD CITY, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its third quarter 2022 financial results will be released after market close on Tuesday, November 8th, 2022. Starting at 5:00 p.m. Eastern Time on Nov
Read more →CHRSCoherus and Junshi Biosciences Announce Publication of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, in the Journal of Clinical Oncology
– Toripalimab in combination with chemotherapy was associated with significant improvements in PFS and OS compared with chemotherapy alone in patients with advanced NSCLC without EGFR/ALK mutations, regardless of PD-L1 expression – Supports combination development of toripalimab
Read more →CHRSCoherus to Launch CIMERLI™ (ranibizumab-eqrn) in the United States on October 3, 2022
- CIMERLI is the first and only FDA-approved biosimilar interchangeable with Lucentis® (ranibizumab injection) for all indications, with 12 months of interchangeability exclusivity - - Interchangeability designation and clinical equivalence to Lucentis provides confidence that e
Read more →CHRSCoherus BioSciences Management to Present at H.C. Wainwright 24th Annual Global Investment Conference
REDWOOD CITY, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will participate at the H.C. Wainwright 24th Annual Global Investment Conference on Wednesday, September 14 at 10:00 am ET. An aud
Read more →CHRS▲ +5.2%on this news· ran to +18% by day 1
Coherus BioSciences Reports Second Quarter 2022 Results and Provides Business Update - Commercial launch of CIMERLI planned for early October 2022 - - PDUFA date for toripalimab BLA is
Coherus BioSciences Reports Second Quarter 2022 Results and Provides Business Update - Commercial launch of CIMERLI planned for early October 2022 - - PDUFA date for toripalimab BLA is December 23, 2022 - - Commercial preparation underway for planned July 2023 launch of YUSIMR
Read more →CHRSCoherus BioSciences to Report Second Quarter 2022 Financial Results on August 4th, 2022
REDWOOD CITY, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its second quarter 2022 financial results will be released after market close on Thursday, August 4th, 2022. Starting at 5 p.m. ET, Coherus’ managemen
Read more →CHRSCoherus and Junshi Biosciences Announce FDA Acceptance of Resubmission of BLA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma
- FDA has set a target action date of December 23, 2022 for the toripalimab BLA - - Toripalimab will be the first and only immuno-oncology agent for NPC in U.S., if approved - REDWOOD CITY, Calif., and SHANGHAI, China, July 06, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc.
Read more →CHRS▼ -9%on this news
Coherus BioSciences Appoints Dr. Jill O’Donnell-Tormey to its Board of Directors
- Dr. O’Donnell-Tormey is a cancer immunology key opinion leader with more than 30 years leading the Cancer Research Institute’s efforts to advance cancer immunotherapies - REDWOOD CITY, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Coherus Biosciences, Inc. (“Coherus”, Nasdaq: CHRS)
Read more →CHRS▲ +6.1%on this newsshared move
Coherus BioSciences Management to Present at Upcoming Investor Conferences
REDWOOD CITY, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), announced today that senior management will present at the following investor conferences in May. BofA Securities 2022 Healthcare Conference on Thursday, May 12 at 3:00 p.
Read more →CHRS▼ -9.3%on this newsshared move
Coherus BioSciences Reports First Quarter 2022 Results - CIMERLI BLA review progressing toward August 2022 action date - - Toripalimab BLA resubmission expected by mid-summer - - UDENYCA delivers 1 st quarter 2022 net sa
Coherus BioSciences Reports First Quarter 2022 Results - CIMERLI BLA review progressing toward August 2022 action date - - Toripalimab BLA resubmission expected by mid-summer - - UDENYCA delivers 1st quarter 2022 net sales of $60.1 million - - 2022 R&D and SG&A expense guidan
Read more →CHRS▼ -9.3%on this newsshared move
Coherus BioSciences Appoints Charlie Newton to Board of Directors
- Biotechnology Chief Financial Officer and highly regarded former healthcare investment banker brings decades of industry experience to Coherus’ immuno-oncology strategy execution - REDWOOD CITY, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or t
Read more →CHRS▲ +7.1%on this newsshared move
Coherus and Junshi Biosciences Receive Complete Response Letter from U.S. FDA for Toripalimab BLA
- The CRL requests a quality process change Coherus and Junshi believe is readily addressable - - BLA resubmission anticipated by mid-summer 2022 with expected six month FDA review timeline - - Onsite inspections in China, impeded to date by COVID-19-related travel restrictions
Read more →CHRSCoherus BioSciences to Report First Quarter 2022 Financial Results on May 5th, 2022
REDWOOD CITY, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its first quarter 2022 financial results will be released after the close of the United States financial markets on Thursday, May 5th, 2022. Starting
Read more →CHRSCoherus and Junshi Biosciences Announce PD-1 Inhibitor Toripalimab Granted Orphan Drug Designation for Small Cell Lung Cancer in the United States
REDWOOD CITY, Calif., and SHANGHAI, China, April 14, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) and Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) announced today that the United States Food and Drug Adminis
Read more →CHRSCoherus and Junshi Biosciences Present Results of Phase 3 Study of Toripalimab in First Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma at 2022 AACR Annual Meeting
SHANGHAI, China, and REDWOOD CITY, Calif., April 08, 2022 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) announced the results of the prespecified final progression-f
Read more →CHRS▲ +6.6%on this news
Coherus Highlights Anticipated New Product Launches and Immuno-oncology Growth Strategy at Analyst Day Event
— Multiple near-term anticipated product launches and development of innovative immuno-oncology pipeline position Coherus for long-term growth – — Introducing 2026 revenue target of $1.2 billion in annual net sales from Coherus' diversified product portfolio – REDWOOD CITY, Cal
Read more →CHRSCoherus BioSciences to Highlight New Product Pipeline, Cancer Immunotherapy Development Plans at March 29, 2022 Analyst Day Event
REDWOOD CITY, Calif., March 22, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that Coherus plans to host an Analyst Day on March 29, 2022 at 9:30 a.m. ET in New York City. Coherus executives and scientists will provide updates on th
Read more →CHRSCoherus BioSciences Appoints Rosh Dias, MD, MRCP, Chief Medical Officer
REDWOOD CITY, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: “CHRS”, “the Company”, “Coherus”) today announced Rosh Dias, MD, MRCP, has been appointed Chief Medical Officer. Dr. Dias will serve as a member of the Company's executive leadership team
Read more →CHRSCoherus and Junshi Biosciences Announce Positive Results from Phase 3 Esophageal Cancer Study of Toripalimab Published in Cancer Cell
- Toripalimab plus chemotherapy demonstrates improvement in co-primary endpoints of PFS and OS in patients with advanced ESCC - - PFS and OS benefits were observed across all PD-L1 expression subgroups, including in patients with low PD-L1 expression - REDWOOD CITY, Calif., and
Read more →CHRSCoherus Management to Present at Upcoming Investor Conferences
REDWOOD CITY, Calif., March 04, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the following investor conferences in March. 42nd Annual Cowen Health Care Conference on Wednesday, March 9 at 10:
Read more →CHRSCoherus BioSciences Reports Fourth Quarter and Full Year 2021 Results - YUSIMRY (adalimumab-aqvh), Coherus' second product, approved by FDA on
Coherus BioSciences Reports Fourth Quarter and Full Year 2021 Results - YUSIMRY (adalimumab-aqvh), Coherus' second product, approved by FDA on December 17, 2021 - - BLAs under FDA review for PD-1 inhibitor toripalimab and CIMERLI (ranibizumab-ranq) - - New FDA filings expected
Read more →CHRSCoherus Names Paul Reider Chief Commercial Officer
REDWOOD CITY, Calif., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: “CHRS”, “the Company”, “Coherus”) today announced Paul Reider has been named Chief Commercial Officer. Mr. Reider previously held the position of Executive Vice President of Commercial Oper
Read more →CHRSCoherus BioSciences to Report Fourth Quarter and Full Year 2021 Financial Results on February 17th, 2022
REDWOOD CITY, Calif., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its fourth quarter and full year 2021 financial results will be released after market close on Thursday, February 17, 2022. Starting at 5 p.m. ET, Coh
Read more →CHRSCoherus BioSciences Appoints Health Care Payer Expert Lee N. Newcomer, M.D., to Board of Directors
REDWOOD CITY, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS) today announced the appointment of board-certified oncologist and seasoned healthcare executive Lee N. Newcomer, M.D., to its Board of Directors effective
Read more →CHRSCoherus and Junshi Biosciences Expand Immuno-Oncology Collaboration to Include TIGIT-Targeted Antibody Coherus and Junshi Biosciences plan to evaluate the toripalimab + JS006 combination in clinical trials in multiple tu
Coherus and Junshi Biosciences Expand Immuno-Oncology Collaboration to Include TIGIT-Targeted Antibody REDWOOD CITY, Calif., and SHANGHAI, China, Jan. 10, 2022 (GLOBE NEWSWIRE) Coherus BioSciences, Inc. ( Coherus , Nasdaq: CHRS) and Shanghai Junshi Biosciences Co., Ltd. ( Juns
Read more →CHRSCoherus BioSciences Secures Credit Financing with Pharmakon Advisors Balance sheet strengthened to support commercial launches of as many as five new products in 2022 and 2023
Coherus BioSciences Secures Credit Financing with Pharmakon Advisors Balance sheet strengthened to support commercial launches of as many as five new products in 2022 and 2023 REDWOOD CITY, Calif., Jan. 7, 2022 (GLOBE NEWSWIRE) Coherus BioSciences, Inc. (Coherus or the Company
Read more →CHRSCoherus BioSciences Management to Present at the 40th Annual J.P. Morgan Healthcare Conference
REDWOOD CITY, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 9 a.m. EST / 6 a.m. PST. T
Read more →CHRSCoherus Announces U.S. FDA Approval of YUSIMRY™ (adalimumab-aqvh)
- Approved for all eligible indications of the reference biological product, Humira® (adalimumab) - - YUSIMRY is Coherus' second FDA-approved product - REDWOOD CITY, Calif., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: “CHRS”, “the Company”, “Coherus”) a
Read more →CHRSCoherus BioSciences Appoints Theresa LaVallee, Ph.D., Chief Development Officer
REDWOOD CITY, Calif., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced the addition of Theresa LaVallee, Ph.D. as its Chief Development Officer. Dr. LaVallee will serve as a member of the Company’s executive leadership team and oversee a
Read more →CHRSCoherus and Junshi Biosciences Announce Positive Interim Overall Survival Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer
SHANGHAI, China and REDWOOD CITY, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced positive results of an interim analysis of ov
Read more →CHRSCoherus and Junshi Biosciences Announce Toripalimab Granted Orphan Drug Designation in the United States for Esophageal Cancer
REDWOOD CITY, Calif. and SHANGHAI, China, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) and Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) announced today that the United States Food and Drug Administr
Read more →CHRSCoherus BioSciences Reports Third Quarter 2021 Results - Key milestones achieved driving near-term commercial product portfolio expansion - - Three BLAs now under FDA review: PD-1 inhibitor toripalimab, biosimilar Lucent
Coherus BioSciences Reports Third Quarter 2021 Results - Key milestones achieved driving near-term commercial product portfolio expansion - - Three BLAs now under FDA review: PD-1 inhibitor toripalimab, biosimilar Lucentis , biosimilar Humira - - Multiple additional applicatio
Read more →CHRSCoherus BioSciences Announces CMS Has Extended Enhanced Medicare Reimbursement for UDENYCA in the 340B Hospital Setting Through Year-End 2022
REDWOOD CITY, Calif., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that the Centers for Medicare & Medicaid Services (“CMS”) will continue to provide increased Medicare reimbursement in the 340B outpatient hospital setting
Read more →CHRSCoherus and Junshi Biosciences Announce FDA Acceptance of BLA Filing for Toripalimab for Treatment of Nasopharyngeal Carcinoma
FDA has granted the toripalimab BLA Priority Review with a target action date of April 2022 REDWOOD CITY, Calif. and SHANGHAI, China, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) and Shanghai Junshi Biosciences Co., Ltd. (“Junshi Bioscie
Read more →CHRSCoherus BioSciences to Report Third Quarter 2021 Financial Results on November 8th
REDWOOD CITY, Calif., Oct. 29, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its third quarter 2021 financial results will be released after market close on Monday, November 8, 2021. Starting at 5 p.m. ET, Coherus’ management t
Read more →CHRSCoherus BioSciences Mourns the Passing of Board Member Alan C. Mendelson
Coherus BioSciences Mourns the Passing of Board Member Alan C. Mendelson REDWOOD CITY, Calif., Oct. 11, 2021 (GLOBE NEWSWIRE) It is with profound sadness that Coherus BioSciences, Inc. (Nasdaq: CHRS) announces the unexpected passing of board member Alan C. Mendelson. He had bee
Read more →CHRSCoherus Announces Positive Results of UDENYCA On-Body Injector Clinical Trial
- UDENYCA® On-Body Injector (OBI) Achieved Both Pharmacokinetic and Pharmacodynamic Bioequivalence in Randomized Clinical Trial - Coherus plans to seek U.S. marketing authorization for the UDENYCA® OBI in 2022 REDWOOD CITY, Calif., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Coherus BioS
Read more →CHRSCoherus Announces BLA Filing for Lucentis (ranibizumab) Biosimilar Candidate Accepted by FDA for Review
FDA has set a target action date of August 2, 2022 for the CHS-201 BLA REDWOOD CITY, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced the United States Food and Drug Administration (FDA) has accepted for review the 351
Read more →CHRSCoherus BioSciences Mourns the Passing of Board Member Dr. Samuel Nussbaum
Coherus BioSciences Mourns the Passing of Board Member Dr. Samuel Nussbaum REDWOOD CITY, Calif., Sept. 29, 2021 (GLOBE NEWSWIRE) It is with profound sadness that Coherus BioSciences, Inc. (Nasdaq: CHRS) announces the passing of board member Samuel Nussbaum, M.D. During his dist
Read more →CHRSCoherus and Junshi Biosciences to Present Positive Progression Free Survival and Overall Survival Results from JUPITER-06, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma
- Interim results to be presented September 17 at the European Society for Medical Oncology (ESMO) Congress 2021 - - Data support the use of toripalimab with chemotherapy as first-line therapy for patients with ESCC – - Coherus and Junshi Biosciences plan to submit a BLA supple
Read more →CHRSCoherus and Junshi Biosciences Announce Results from Phase 3 Study of Toripalimab Published in September Issue of Nature Medicine
REDWOOD CITY, Calif., and SHANGHAI, China, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) and Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) today announced publication of a cover article in the Septemb
Read more →CHRSCoherus Management to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
REDWOOD CITY, Calif., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the 23rd Annual H.C. Wainwright Global Investment Conference. The presentation will be made available at 7 a.m. ET
Read more →CHRSCoherus BioSciences Announces Upcoming Medical Conference Presentations
REDWOOD CITY, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced upcoming medical conference presentations. Toripalimab clinical data will be presented September 13 at the IASLC 2021 World Conference on Lung Cancer and
Read more →CHRSCoherus and Junshi Biosciences Announce Completion of Rolling BLA Submission to U.S. FDA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma
SHANGHAI, China, and REDWOOD CITY, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus Biosciences, Inc. (“Coherus”, Nasdaq: CHRS) announced today the completion of the rolling submission of
Read more →CHRSCoherus and Junshi Biosciences Announce Positive Interim Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer
– Toripalimab plus chemotherapy met primary endpoint with significant improvement in PFS compared to chemotherapy alone – - Data support the use of toripalimab with chemotherapy as first-line therapy for patients with NSCLC - - Study to be presented September 13 at IASLC 2021 W
Read more →CHRSCoherus BioSciences Reports Second Quarter 2021 Financial Results and Immuno-oncology and Biosimilar Pipeline Progress -1 st line nasopharyngeal indication and 2 nd /3 rd line indications to be concurrently submitted 3Q
Coherus BioSciences Reports Second Quarter 2021 Financial Results and Immuno-oncology and Biosimilar Pipeline Progress -1st line nasopharyngeal indication and 2nd/3rd line indications to be concurrently submitted 3Q 2021 in the toripalimab BLA - - CHS-201 (Lucentis biosimilar
Read more →CHRSCoherus BioSciences to Report Second Quarter 2021 Financial Results on August 5th
REDWOOD CITY, Calif., July 26, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its second quarter 2021 financial results will be released after market close on Thursday, August 5, 2021. Starting at 5 p.m. ET, Coherus’ management
Read more →CHRSCoherus BioSciences Names Physician-Scientist Ildiko Csiki, M.D., Ph.D., Chair of its Scientific Advisory Board
REDWOOD CITY, Calif., July 21, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced the appointment of Ildiko Csiki, M.D., Ph.D., a leader in the field of immuno-oncology research and drug development, as Chair of its Scientific Advisory Bo
Read more →CHRSCoherus and Junshi Biosciences to Host Virtual Investor Event to Discuss Toripalimab and ASCO 2021 Highlights
SHANGHAI, China, and REDWOOD CITY, Calif., June 04, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced that the companies will host a virtual investo
Read more →CHRSCoherus and Junshi Biosciences Announce Toripalimab in Combination with Chemotherapy Met Primary Progression Free Survival (PFS) Endpoint as First Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
– In pivotal Phase 3 JUPITER-02 study, toripalimab plus chemotherapy significantly improved PFS compared to chemotherapy alone in high and low PD-L1 expression subgroups – – Although median overall survival (OS) analysis was not yet mature, a 40% reduction in risk of death was
Read more →CHRSCoherus BioSciences to Present at the Bank of America Health Care Conference
REDWOOD CITY, Calif., May 07, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the upcoming Bank of America Health Care Conference on Wednesday, May 12, 2021 at 1:15 p.m. EST / 10:15 a.m. PST. Th
Read more →CHRSCoherus BioSciences Reports First Quarter 2021 Financial Results and Immuno-oncology and Biosimilar Pipeline Progress - Junshi Biosciences transaction is followed by rapid toripalimab progress including initiation of fir
Coherus BioSciences Reports First Quarter 2021 Financial Results and Immuno-oncology and Biosimilar Pipeline Progress - Junshi Biosciences transaction is followed by rapid toripalimab progress including initiation of first BLA submission to the U.S. FDA, positive interim analys
Read more →CHRSCoherus BioSciences to Report First Quarter 2021 Financial Results on May 6th
REDWOOD CITY, Calif., April 30, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today announced that its first quarter 2021 financial results will be released after market close on Thursday, May 6, 2021. Starting at 4:30 p.m. ET, Coh
Read more →CHRSCoherus Announces Toripalimab Achieved Primary Endpoints of Progression Free Survival and Overall Survival in Interim Analysis of Phase 3 Clinical Trial in First-Line Esophageal Squamous Cell Carcinoma
REDWOOD CITY, Calif., April 23, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS) has received notice from immuno-oncology partner Junshi Biosciences that the Independent Data Monitoring Committee of the JUPITER-06 clinical trial has determined that toripalimab, a
Read more →CHRSCoherus Announces Closing of Sale of Common Stock to Immuno-Oncology Partner Junshi Biosciences
REDWOOD CITY, Calif., April 20, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced the closing of the sale of Coherus common stock to Junshi Biosciences. Under the terms of the February 2, 2021 stock purchase agreement, Coherus has recei
Read more →CHRSCoherus BioSciences Reports Fourth Quarter and Full Year 2020 Financial Results - Product revenues of $476 million for full year 2020, $110 million for the fourth quarter of 2020 - - Expanding late-stage opportunities wi
Coherus BioSciences Reports Fourth Quarter and Full Year 2020 Financial Results - Product revenues of $476 million for full year 2020, $110 million for the fourth quarter of 2020 - - Expanding late-stage opportunities with Junshi Biosciences immuno-oncology collaboration with f
Read more →CHRSCoherus BioSciences to Report Fourth Quarter and Full Year 2020 Financial Results on February 24th
REDWOOD CITY, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today announced that it will release fourth quarter and full year 2020 financial results after the market closes on Wednesday, February 24, 2021. The news
Read more →CHRSCoherus BLA Filing for Adalimumab Biosimilar Candidate Accepted by FDA for Review
REDWOOD CITY, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: “CHRS”, “the Company”, “Coherus”) announced that the United States Food and Drug Administration (“FDA”) has accepted for review the 351(k) Biologics License Application (“BLA”) for CHS-1420
Read more →CHRSCoherus Announces CFO Transition Plans
REDWOOD CITY, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: “CHRS”, “the Company”, “Coherus”) announced that Chief Financial Officer Jean-Frédéric Viret, Ph.D. will resign from Coherus effective March 7, 2021 to pursue another opportunity. McDavid S
Read more →CHRSCoherus BioSciences to Receive $50 million Strategic Investment from Immuno-Oncology Partner Junshi Biosciences
REDWOOD CITY, Calif., Feb. 02, 2021 (GLOBE NEWSWIRE) -- A day after announcing their new immuno-oncology collaboration, Coherus BioSciences, Inc. (Nasdaq: CHRS) (“Coherus”) announced that Shanghai Junshi Biosciences Co., Ltd (HK: 1877; SH: 688180) (“Junshi Biosciences”) intends t
Read more →CHRSCoherus BioSciences to expand late-stage pipeline to immuno-oncology with in-license of Junshi Biosciences' PD-1, toripalimab, in United States and Canada - Coherus to pay $150 million upfront for US and Canada rights to
Coherus BioSciences to expand late-stage pipeline to immuno-oncology with in-license of Junshi Biosciences' PD-1, toripalimab, in United States and Canada - Coherus to pay $150 million upfront for US and Canada rights to toripalimab, an extensively studied, late-stage anti-PD-1
Read more →CHRSCoherus BioSciences Appoints Alan Mendelson and Mark Stolper to Board of Directors
Coherus BioSciences Appoints Alan Mendelson and Mark Stolper to Board of Directors REDWOOD CITY, Calif., January 7, 2021 - Coherus BioSciences, Inc. ("Coherus", Nasdaq: CHRS), today announced the appointments of Alan C. Mendelson and Mark D. Stolper to its Board of Directors eff
Read more →CHRSCoherus BioSciences Management to Present at the 39th Annual J.P. Morgan Healthcare Conference
REDWOOD CITY, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the virtual 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 10:50 a.m. EST / 7:50 a.m.
Read more →CHRSCoherus BioSciences Reports Third Quarter 2020 Financial Results - Third Quarter UDENYCA Net Sales of $113.6 Million - - Net Income of $27.9 Million - - Non-GAAP Net Income of $39.7 Million
Coherus BioSciences Reports Third Quarter 2020 Financial Results - Third Quarter UDENYCA Net Sales of $113.6 Million - - Net Income of $27.9 Million - - Non-GAAP Net Income of $39.7 Million - REDWOOD CITY, Calif., November 5, 2020 - Coherus BioSciences, Inc. ("Coherus" or the
Read more →CHRSCoherus BioSciences to Report Third Quarter Financial Results on November 5th
REDWOOD CITY, Calif., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its third quarter 2020 financial results will be released after market close on Thursday, November 5, 2020. Starting at 4:30 p.m. EST, Coherus’ manage
Read more →CHRSCoherus BioSciences Reports Second Quarter 2020 Financial Results - Second Quarter UDENYCA Net Sales of $135.7 Million - - Net Income of $59.0 Million - - Non-GAAP Net Income of $68.3 Million
Coherus BioSciences Reports Second Quarter 2020 Financial Results - Second Quarter UDENYCA Net Sales of $135.7 Million - - Net Income of $59.0 Million - - Non-GAAP Net Income of $68.3 Million - REDWOOD CITY, Calif., August 6, 2020 - Coherus BioSciences, Inc. ("Coherus" or the
Read more →CHRSCoherus BioSciences Appoints Kimberly Tzoumakas, J.D. to Board of Directors
Coherus BioSciences Appoints Kimberly Tzoumakas, J.D. to Board of Directors REDWOOD CITY, Calif., August 3, 2020 - Coherus BioSciences, Inc. ("Coherus", Nasdaq: CHRS), today announced the appointment of Kimberly Tzoumakas, J.D. to its Board of Directors effective July 30, 2020.
Read more →CHRSCoherus BioSciences to Report Second Quarter Financial Results on August 6th
REDWOOD CITY, Calif., July 16, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its second quarter 2020 financial results will be released after market close on Thursday, August 6, 2020. Starting at 4:30 p.m. ET, Coherus’ manageme
Read more →CHRSCoherus BioSciences Reports First Quarter 2020 Financial Results - First Quarter UDENYCA Net Sales of $116.2 Million - -Net Income of $35.6 Million - - Non-GAAP Net Income of $49.8 Million
Coherus BioSciences Reports First Quarter 2020 Financial Results - First Quarter UDENYCA Net Sales of $116.2 Million - -Net Income of $35.6 Million - - Non-GAAP Net Income of $49.8 Million - REDWOOD CITY, Calif., May 7, 2020 - Coherus BioSciences, Inc. ("Coherus" or the "Comp
Read more →CHRSCoherus BioSciences Management to Present at BofA Securities 2020 Health Care Conference
REDWOOD CITY, Calif., May 04, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will make a virtual presentation at BofA Securities 2020 Health Care Conference on Thursday, May 14, 2020 at 1:00 p.m. ET. The audio
Read more →CHRSCoherus BioSciences to Report First Quarter Financial Results on May 7th
REDWOOD CITY, Calif., April 22, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that its first quarter 2020 financial results will be released after market close on Thursday, May 7, 2020. Starting at 4:30 p.m. ET, Coh
Read more →CHRSCoherus BioSciences Prices $200.0 Million Convertible Senior Subordinated Notes Offering
REDWOOD CITY, Calif., April 15, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced the pricing of its offering of $200,000,000 aggregate principal amount of 1.500% convertible senior subordinated notes due 2026 (the “not
Read more →CHRSCoherus BioSciences Announces Proposed Convertible Senior Subordinated Notes Offering
Coherus BioSciences Announces Proposed Convertible Senior Subordinated Notes Offering REDWOOD CITY, Calif.-April 14, 2020-(GLOBE NEWSWIRE)-Coherus BioSciences, Inc. ("Coherus" or the "Company", Nasdaq: CHRS), today announced its intention to offer, subject to market and other
Read more →CHRSCoherus BioSciences Provides First Quarter 2020 Financial Update and Fiscal Year 2020 COVID-19 Impact Insights
REDWOOD CITY, Calif., April 13, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today announced preliminary unaudited revenue for UDENYCA® and net income for the quarter ended March 31, 2020. Coherus also provided an update on the im
Read more →CHRSCoherus BioSciences Management to Present at Barclays Global Healthcare Conference 2020
REDWOOD CITY, Calif., March 05, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at Barclays Global Healthcare Conference 2020 on Tuesday, March 10, 2020 at 8:30 a.m. ET, being held in Miami. The au
Read more →CHRSCoherus BioSciences Reports Fourth Quarter and Full Year 2019 Financial Results - Full Year UDENYCA Sales of $356.1 Million - - Full Year Cash Flow from Operating Activities of $28.4 million
Coherus BioSciences Reports Fourth Quarter and Full Year 2019 Financial Results - Full Year UDENYCA Sales of $356.1 Million - - Full Year Cash Flow from Operating Activities of $28.4 million - REDWOOD CITY, Calif., February 27, 2020 - Coherus BioSciences, Inc. ("Coherus" or t
Read more →CHRSCoherus BioSciences Management to Present at the 40th Annual Cowen Healthcare Conference
REDWOOD CITY, Calif., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the 40th Annual Cowen Healthcare Conference on Tuesday, March 3, 2020 at 9:20 a.m. ET, being held in Boston. The au
Read more →CHRSCoherus BioSciences to Report Fourth Quarter and Full Year Financial Results on February 27th
REDWOOD CITY, Calif., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today announced that its fourth quarter and full year 2019 financial results will be released after market close on Thursday, February 27, 2020. Starting
Read more →CHRSCoherus Acquires Commercial Rights for Avastin Biosimilar in the United States
REDWOOD CITY, Calif., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced the Company has entered into a licensing agreement with Innovent Biologics, (Suzhou) Co., Ltd., (“Innovent”), a leading biopharmaceutical
Read more →CHRSCoherus BioSciences Management to Present at the 38th Annual J.P. Morgan Healthcare Conference
REDWOOD CITY, Calif., Jan. 03, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020 at 11:00 a.m. PT, being held in San F
Read more →CHRSCoherus BioSciences Management to Present at Two Upcoming Investor Healthcare Conferences
REDWOOD CITY, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at two upcoming investor healthcare conferences. Management will deliver a company presentation at the Jefferies 2019
Read more →CHRSCoherus Acquires Commercial Rights for Leading Lucentis Biosimilar in the United States
REDWOOD CITY, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced the Company has acquired exclusive rights from Bioeq IP AG, (“Bioeq”) a Swiss biopharmaceutical joint venture, to commercialize Bioeq’s bi
Read more →CHRSCoherus BioSciences Reports Corporate Highlights and Third Quarter 2019 Financial Results
Coherus BioSciences Reports Corporate Highlights and Third Quarter 2019 Financial Results REDWOOD CITY, Calif., November 6, 2019 - Coherus BioSciences, Inc. ("Coherus" or the "Company", Nasdaq: CHRS), today reviewed corporate highlights and reported financial results for the qu
Read more →CHRSCoherus BioSciences to Report Third Quarter Financial Results on November 6th
REDWOOD CITY, Calif., Oct. 15, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today announced that its third quarter 2019 financial results will be released after market close on Wednesday, November 6, 2019. Starting at 4:30 p.m. ET
Read more →CHRSCoherus BioSciences Management to Present at Two Investor Healthcare Conferences in September
REDWOOD CITY, Calif., Aug. 21, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that senior management will present at two upcoming investor healthcare conferences. Management will deliver a company presentation at the Baird 2019 Global Healthca
Read more →CHRSCoherus BioSciences Reports Corporate Highlights and Second Quarter 2019 Financial Results - Company is Profitable and Cash flow Positive from Operations for Second Quarter - - UDENYCA is the Market Leading Pegfilgrastim
Coherus BioSciences Reports Corporate Highlights and Second Quarter 2019 Financial Results - Company is Profitable and Cash flow Positive from Operations for Second Quarter - - UDENYCA is the Market Leading Pegfilgrastim Biosimilar with Approximately 13% Market Share - REDWOO
Read more →CHRSCoherus BioSciences Reports Victory in Pegfilgrastim Patent Dispute
REDWOOD CITY, Calif., July 29, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today announced that the United States Court of Appeals for the Federal Circuit has affirmed the decision of the United States District Court for the Dist
Read more →CHRSCoherus BioSciences to Report Second Quarter Financial Results on August 1st
REDWOOD CITY, Calif., July 08, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today announced that its second quarter 2019 financial results will be released after market close on Thursday, August 1, 2019. Starting at 4:30 p.m. ET,
Read more →CHRSCoherus BioSciences Announces Unaudited Second Quarter 2019 UDENYCA Net Sales of $79 Million to $84 Million
Coherus BioSciences Announces Unaudited Second Quarter 2019 UDENYCA Net Sales of $79 Million to $84 Million REDWOOD CITY, Calif., July 8, 2019 Coherus BioSciences, Inc. ( Coherus or the Company , Nasdaq: CHRS), today announced that UDENYCA preliminary unaudited net sales for
Read more →CHRSCoherus BioSciences Production Exceeds Four-Hundred Thousand UDENYCA (pegfilgrastim-cbqv) Pre-Filled Syringes
REDWOOD CITY, Calif., July 01, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or “the Company,” Nasdaq: CHRS), is pleased to announce that it has produced over 400,000 UDENYCA® pre-filled syringes to date. The cumulative production of 400,000 UDENYCA® pre-filled s
Read more →CHRSCoherus BioSciences Management to Present at Jefferies 2019 Global Healthcare Conference
REDWOOD CITY, Calif., May 22, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that senior management will present at the Jefferies 2019 Global Healthcare Conference in New York City on Tuesday, June 5, 2019 at 10:00 a.m. ET. The audio portion o
Read more →CHRSCoherus BioSciences Reports Corporate Highlights and First Quarter 2019 Financial Results
Coherus BioSciences Reports Corporate Highlights and First Quarter 2019 Financial Results REDWOOD CITY, Calif., May 9, 2019 Coherus BioSciences, Inc. ( Coherus or the Company , Nasdaq: CHRS), today reviewed corporate highlights and reported financial results for the quarter en
Read more →CHRSCoherus BioSciences and Amgen Settle Trade Secrets Action - Coherus Continues to Commercialize UDENYCA Across All Segments
Coherus BioSciences and Amgen Settle Trade Secrets Action - Coherus Continues to Commercialize UDENYCA Across All Segments - REDWOOD CITY, Calif., May 2, 2019 Coherus BioSciences, Inc. ( Coherus , Nasdaq: CHRS), today announced that Amgen and Coherus have settled the trade sec
Read more →CHRSCoherus BioSciences to Report First Quarter Financial Results on May 9th
REDWOOD CITY, Calif., April 05, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its first quarter 2019 financial results will be released after market close on Thursday, May 9, 2019. Starting at 4:30 p.m. ET, Coherus’ management
Read more →CHRSCoherus BioSciences Announces Unaudited First Quarter 2019 UDENYCA Net Sales
Coherus BioSciences Announces Unaudited First Quarter 2019 UDENYCA Net Sales REDWOOD CITY, Calif., April 5, 2019 Coherus BioSciences, Inc. ( Coherus , Nasdaq: CHRS), today announced that UDENYCA preliminary unaudited net sales for the quarter that ended March 31, 2019 are expec
Read more →CHRSCoherus BioSciences Management to Present at H.C. Wainwright & Co. Global Life Sciences Conference
REDWOOD CITY, Calif., March 28, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that senior management will present at the H.C. Wainwright & Co. Global Life Sciences Conference in London on Tuesday, April 9, 2019 at 12:10 p.m. GMT. The audio po
Read more →CHRSCoherus BioSciences Appoints Thomas Fitzpatrick Chief Legal Officer
REDWOOD CITY, Calif., March 18, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced the addition of Thomas Fitzpatrick as its Chief Legal Officer. Mr. Fitzpatrick brings more than 20 years of executive-level legal experience to his role as leader o
Read more →CHRSCoherus BioSciences Receives Transitional Pass-Through Status from
Coherus BioSciences Receives Transitional Pass-Through Status from CMS CITY, Calif., March 18, 2019 Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that the Centers for Medicare and Medicaid Services (CMS) approved UDENYCA (pegfilgrastim-cbqv) biosimilar for transitio
Read more →CHRSCoherus BioSciences Reports Fourth Quarter and Full Year 2018 Financial Results
Coherus BioSciences Reports Fourth Quarter and Full Year 2018 Financial Results REDWOOD CITY, Calif., February 28, 2019 Coherus BioSciences, Inc. (Nasdaq: CHRS), today reviewed corporate events and reported financial results for the quarter and full year ended December 31, 2018
Read more →CHRSCoherus BioSciences Management to Present at Two Investor Healthcare Conferences in March
REDWOOD CITY, Calif., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that senior management will present at two upcoming investor healthcare conferences. Management will deliver a company presentation at the 38th Cowen & Company Healt
Read more →CHRSCoherus BioSciences to Report Fourth Quarter and Full Year 2018 Financial Results on February 28th
REDWOOD CITY, Calif., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that its fourth quarter and full year 2018 financial results will be released after market close on Thursday, February 28, 2019. Starting at 4:30 p.m. ET, Coherus’ ma
Read more →CHRSCoherus BioSciences Announces Global Settlement with AbbVie Securing Rights to Commercialize its Adalimumab Biosimilar Candidate, CHS-1420
REDWOOD CITY, Calif., Jan. 25, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), a commercial biosimilar company, today announced it has executed settlement agreements with AbbVie Inc. that grant Coherus global, non-exclusive license rights under AbbVie’s intelle
Read more →CHRSCoherus BioSciences Announces Filing of Patent Infringement Suit Against Amgen Directed to Amgen’s Humira Biosimilar Formulation
REDWOOD CITY, Calif., Jan. 25, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), a commercial biosimilar company, today announced it has filed suit against Amgen in the United States District Court (Delaware) alleging that Amgen’s Humira® biosimilar, Amgevita™, i
Read more →CHRSCoherus BioSciences Secures $75 Million Credit Financing with HealthCare Royalty Partners
REDWOOD CITY, Calif., Jan. 07, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), a commercial biosimilar company, today announced that it has entered into a $75 million senior secured credit facility agreement with Healthcare Royalty Partners. “We are pleased to
Read more →CHRSCoherus BioSciences Management to Present at The 37th Annual J.P. Morgan Healthcare Conference
REDWOOD CITY, Calif., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that senior management will present at the 37th annual J.P. Morgan healthcare conference on Tuesday, January 8, 2017 at 7:30 a.m. PT being held in San Francisco. The
Read more →CHRSCoherus BioSciences Appoints Darlene Horton, M.D., Chief Medical and Regulatory Affairs Officer
REDWOOD CITY, Calif., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced the addition of Darlene Horton, M.D. as Chief Medical and Regulatory Affairs Officer. She assumed her role on January 1, 2019. “We are very pleased that Dr. Horton h
Read more →CHRSCoherus BioSciences Announces Apexus Contract Agreement for 340B Hospitals and Clinics, and Q-Code Issuance from CMS
REDWOOD CITY, Calif., Nov. 30, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that the company has executed a 340B prime vendor program contract agreement with Apexus, LLC. Apexus is a recognized leader in the ambulatory hospital outpatient set
Read more →CHRSCoherus BioSciences Management to Present at the 27th Annual Credit Suisse Healthcare Conference
REDWOOD CITY, Calif., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that senior management will be presenting at the 27th Annual Credit Suisse Healthcare Conference being held in Scottsdale, Arizona on Thursday, November 15 at 9:45 am
Read more →CHRSCoherus BioSciences Reports Corporate Highlights and Third Quarter 2018 Financial Results
Coherus BioSciences Reports Corporate Highlights and Third Quarter 2018 REDWOOD CITY, Calif., November 8, 2018 Coherus BioSciences, Inc. (Nasdaq: CHRS), today reviewed corporate highlights and reported financial results for the quarter ended September 30, 2018. Third Quarter 2
Read more →CHRSU.S. FDA Approves UDENYCA (pegfilgrastim-cbqv)
U.S. FDA Approves UDENYCA (pegfilgrastim-cbqv) Calif., November 2, 2018 Coherus BioSciences, Inc. (NASDAQ: CHRS), today announced that the U.S. Food and Drug Administration (FDA) has approved UDENYCA (pegfilgrastim-cbqv), the first pegfilgrastim biosimilar approved by both the
Read more →CHRSCoherus BioSciences to Report Third Quarter 2018 Financial Results on November 8th
REDWOOD CITY, Calif., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS) today announced that its third quarter 2018 financial results will be released after market close on Thursday, November 8, 2018. Starting at 4:30 p.m. ET, Coherus’ management will ho
Read more →CHRSCoherus BioSciences Receives European Commission Approval for UDENYCA (Pegfilgrastim Biosimilar)
Coherus BioSciences Receives European Commission Approval for UDENYCA (Pegfilgrastim Biosimilar) Calif., September 25, 2018 Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced the European Commission (EC) has granted marketing authorization to UDENYCA (formerly CHS-1701),
Read more →CHRSCoherus BioSciences Management to Present at the 2018 Cantor Global Healthcare Conference in October
REDWOOD CITY, Calif., Sept. 17, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that senior management will be presenting at the 2018 Cantor Global Healthcare Conference being held in New York on Tuesday, October 2, 2018 at 8:00 am ET. The audi
Read more →CHRSCoherus BioSciences Management to Participate in Two Investor Healthcare Conferences in September
REDWOOD CITY, Calif., Aug. 20, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that senior management will participate in two upcoming investor healthcare conferences in September. Management participation in a fireside chat is scheduled at Bai
Read more →CHRSCoherus BioSciences Reports Corporate Highlights and Second Quarter 2018 Financial Results
Coherus BioSciences Reports Corporate Highlights and Second Quarter 2018 Financial Results REDWOOD CITY, Calif., August 8, 2018 Coherus BioSciences, Inc. (Nasdaq: CHRS), today reviewed corporate highlights and reported financial results for the quarter ended June 30, 2018. Sec
Read more →CHRSCoherus BioSciences Receives Positive CHMP Opinion for UDENYCA (Pegfilgrastim Biosimilar Candidate)
Coherus BioSciences Receives Positive CHMP Opinion for UDENYCA (Pegfilgrastim Biosimilar Candidate) REDWOOD CITY, Calif., July 27, 2018 Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines
Read more →CHRSCoherus BioSciences to Report Second Quarter 2018 Financial Results on August 8th
REDWOOD CITY, Calif., July 24, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that its second quarter 2018 financial results will be released after market close on Wednesday, August 8, 2018. Starting at 4:30 p.m. ET, Coherus’ management will ho
Read more →CHRSU.S. Food and Drug Administration Accepts and Acknowledges Coherus BioSciences Biologics License Application of CHS-1701 (Pegfilgrastim Biosimilar Candidate) for Review
U.S. Food and Drug Administration Accepts and Acknowledges Coherus BioSciences Biologics License Application of CHS-1701 (Pegfilgrastim Biosimilar Candidate) for Review REDWOOD CITY, Calif., May 14, 2018 Coherus BioSciences, Inc. (NASDAQ: CHRS), today announced the U.S. Food a
Read more →CHRSCoherus BioSciences Appoints Samuel Nussbaum, M.D. to Board of Directors
Coherus BioSciences Appoints Samuel Nussbaum, M.D. to Board of Directors Calif., May 10, 2018 Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced the appointment of Samuel Nussbaum, M.D. to its Board of Directors. We are thrilled to have a health care policy and payer ex
Read more →CHRSCoherus BioSciences Reports Corporate Highlights and First Quarter 2018 Financial Results
Coherus BioSciences Reports Corporate Highlights and First Quarter 2018 Financial REDWOOD CITY, Calif., May 10, 2018 Coherus BioSciences, Inc. (Nasdaq: CHRS), today reviewed corporate highlights and reported financial results for the quarter ended March 31, 2018. First Quarter
Read more →CHRSCoherus BioSciences Re-Submits Biologics License Application for CHS-1701 (Pegfilgrastim Biosimilar Candidate)
Coherus BioSciences Re-Submits Biologics License Application for (Pegfilgrastim Biosimilar Candidate) REDWOOD CITY, Calif., May 3, 2018 Coherus BioSciences, Inc. (NASDAQ: CHRS), today announced the re-submission of its biologics license application (BLA) for CHS-1701, a pegfil
Read more →CHRSCoherus BioSciences Management to Present at the Bank of America Merrill Lynch Health Care Conference in Las Vegas, Nevada
REDWOOD CITY, Calif., May 01, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS) today announced that senior management will be presenting at the Bank of America Merrill Lynch Health Care Conference on Wednesday, May 16, 2018 at 11:40 am ET being held in Las Vegas,
Read more →CHRSCoherus BioSciences to Report First Quarter 2018 Financial Results on May 10th
REDWOOD CITY, Calif., April 24, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that its first quarter 2018 financial results will be released after market close on Thursday, May 10, 2018. Starting at 4:30 p.m. EDT, Coherus’ management will host
Read more →CHRSCoherus BioSciences Management to Present at the H.C. Wainwright Annual Global Life Sciences Conference in Monte Carlo, Monaco
REDWOOD CITY, Calif., April 02, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS) today announced that senior management will be presenting at the H.C. Wainwright Annual Life Sciences Conference on Tuesday, April 10, 2018 at 8:10 am ET being held in Monte Carlo, Mo
Read more →CHRSCoherus BioSciences Reports Fourth Quarter and Full Year 2017 Financial Results
Coherus BioSciences Reports Fourth Quarter and Full Year 2017 REDWOOD CITY, Calif., March 8, 2018 Coherus BioSciences, Inc. (Nasdaq: CHRS), today reviewed corporate events and reported financial results for the quarter and full year ended December 31, 2017. Fourth Quarter and
Read more →CHRSCoherus BioSciences to Report Fourth Quarter and Full Year 2017 Financial Results on March 8th
REDWOOD CITY, Calif., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that its fourth quarter and full year 2017 financial results will be released after market close on Thursday, March 8, 2018. At 4:30 p.m. Eastern Time, Coherus’ manag
Read more →CHRSCoherus BioSciences Management to Present at The 36th Annual J.P. Morgan Healthcare Conference
REDWOOD CITY, Calif., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that senior management will present at the 36th annual J.P. Morgan healthcare conference on Monday, January 8, 2017 at 2:00 p.m. PT being held in San Francisco. The a
Read more →CHRSCoherus BioSciences Management to Present at BMO’s Prescriptions for Success Healthcare Conference
REDWOOD CITY, Calif., Dec. 01, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS) today announced that senior management will be participating in a fireside chat at the BMO Prescriptions for Success Healthcare Conference on Thursday, December 14, 2017 at 1:30 p.m. E
Read more →CHRSCoherus BioSciences Reports Third Quarter 2017 Operating and Financial Results
Coherus BioSciences Reports Third Quarter 2017 Operating and Financial Results CITY, Calif., November 6, 2017 Coherus BioSciences, Inc. (Nasdaq: CHRS), today reported financial results and reviewed corporate events for the third quarter ended September 30, 2017. Corporate High
Read more →CHRSCoherus BioSciences Management to Present at Credit Suisse Scottsdale Healthcare Conference
REDWOOD CITY, Calif., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS) today announced that senior management will be participating in a fireside chat at the Credit Suisse Scottsdale Healthcare Conference on Tuesday, November 7, 2017 at 4:45pm ET being he
Read more →CHRSCoherus BioSciences to Report Third Quarter 2017 Financial Results on November 6th
REDWOOD CITY, Calif., Oct. 23, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that its third quarter 2017 financial results will be released after market close on Monday, November 6th, 2017. Starting at 4:30 p.m. EDT, Coherus’ management will h
Read more →CHRSCoherus BioSciences Provides Update on 619 IPR Institution Decision Patent Trial and Appeal Board Denies Institution
Coherus BioSciences Provides Update on 619 IPR Institution Decision Patent Trial and Appeal Board Denies Institution CITY, Calif., September 7, 2017 -- Coherus BioSciences, Inc. (Nasdaq: CHRS) today announced that the Patent Trial and Appeal Board ( PTAB ) of the United States
Read more →CHRSCoherus BioSciences Management to Present at Three Investor Healthcare Conferences in September
REDWOOD CITY, Calif., Sept. 01, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS) today announced that senior management will present at three upcoming investor healthcare conferences. Management participation in a fireside chat is scheduled at the Wells Fargo Hea
Read more →CHRSCoherus BioSciences Announces Positive Topline Results for Clinical Pharmacokinetic Bioequivalence Study for CHS-1420 (Humira Biosimilar Candidate) versus European Marketed Humira in Healthy Subjects
Coherus BioSciences Announces Positive Topline Results for Clinical Pharmacokinetic Bioequivalence Study for CHS-1420 (Humira Biosimilar Candidate) versus European Marketed Humira in Healthy Subjects REDWOOD CITY, Calif., August 28, 2017 Coherus BioSciences, Inc. (NASDAQ: CHR
Read more →CHRSCoherus Secures Private Placement from Temasek
REDWOOD CITY, Calif., Aug. 21, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS) today announced plans to raise up to $150 million in a two tranche private placement, the first tranche of $75 million in aggregate gross proceeds to be completed and funded by August
Read more →CHRSCoherus Secures Private Placement from Temasek First tranche of $75 million secured
Coherus Secures Private Placement from Temasek First tranche of $75 million secured REDWOOD CITY, Calif., August 21, 2017 Coherus BioSciences, Inc. (Nasdaq: CHRS) today announced plans to raise up to $150 million in a two tranche private placement, the first tranche of $75 mil
Read more →CHRSCoherus BioSciences Reports Second Quarter 2017 Corporate Highlights and Financial Results
Coherus BioSciences Reports Second Quarter 2017 Corporate Highlights and Financial Results Calif., August 7, 2017 -- Coherus BioSciences, Inc. (NASDAQ: CHRS), today reviewed corporate events and reported financial results for the quarter ended June 30, 2017. Corporate Highligh
Read more →CHRSCoherus BioSciences Files Petition for Inter Partes Review of ENBREL Patent 8,163,522
REDWOOD CITY, Calif., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that it has filed a petition for Inter Partes Review (“IPR”) in the United States Patent and Trademark Office seeking invalidation of U.S. Patent 8,163,522 (“ ‘522 pat
Read more →CHRSCoherus BioSciences to Report Second Quarter 2017 Financial Results on August 7th
REDWOOD CITY, Calif., July 24, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that its second quarter 2017 financial results will be released after market close on Monday, August 7, 2017. Starting at 4:30 p.m. EDT, Coherus’ management will host
Read more →CHRSCoherus BioSciences Receives Complete Response Letter from FDA for its Biologics License Application for CHS-1701 (Pegfilgrastim Biosimilar Candidate) Management to host a call today at 8:00 a.m. EDT to discuss FDA feedb
Coherus BioSciences Receives Complete Response Letter from FDA for its Biologics License Application for CHS-1701 (Pegfilgrastim Biosimilar Candidate) Management to host a call today at 8:00 a.m. EDT to discuss FDA feedback REDWOOD CITY, Calif., June 12, 2017 Coherus BioScien
Read more →CHRSCoherus BioSciences Management to Present at 36th NASDAQ OMX Investor Program
REDWOOD CITY, Calif., June 01, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that senior management will present at the 36th NASDAQ OMX Investor Program on Thursday, June 15, 2017 in London, UK at 11:30 am GMT. The audio portion of the present
Read more →CHRSCoherus BioSciences Prevails in 135 IPR Decision Patent Trial and Appeal Board Invalidates AbbVie U.S. Patent 8,889,135
Coherus BioSciences Prevails in 135 IPR Decision Patent Trial and Appeal Board Invalidates AbbVie U.S. Patent 8,889,135 REDWOOD CITY, Calif., May 16, 2017 Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that the Patent Trial and Appeal Board ( PTAB ) of the U.S. Pat
Read more →CHRSCoherus BioSciences Prevails in ‘135 IPR Decision
REDWOOD CITY, Calif., May 16, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that the Patent Trial and Appeal Board (“PTAB”) of the U.S. Patent and Trademark Office ruled in favor of Coherus’ petitions for Inter Partes Review (“IPR”) of AbbVie’s
Read more →CHRSCoherus BioSciences Reports First Quarter 2017 Corporate Highlights and Financial Results
Coherus BioSciences Reports First Quarter 2017 Corporate Highlights and Financial Results REDWOOD CITY, Calif., May 8, 2017 Coherus BioSciences, Inc. (NASDAQ: CHRS), today reviewed corporate events and reported financial results for the quarter ended March 31, 2017. Corporate
Read more →CHRSCoherus BioSciences Management to Present at Two Investor Healthcare Conferences in May
REDWOOD CITY, Calif., May 01, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that senior management will present at two upcoming investor healthcare conferences. A fireside chat is scheduled at Deutche Bank’s 42nd Annual Health Care Conference
Read more →CHRSCoherus BioSciences Completes Patent Dance Exchange with Amgen for Neulasta Biosimilar
Coherus BioSciences Completes Patent Dance Exchange with Amgen for Neulasta Biosimilar REDWOOD CITY, Calif., April 25, 2017 Coherus BioSciences, Inc. (Nasdaq: CHRS), announced today that it completed the initial phases of the Biologics Price Competition and Innovation Act (BPC
Read more →CHRSCoherus BioSciences to Report First Quarter 2017 Financial Results on May 8th
REDWOOD CITY, Calif., April 24, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that its first quarter 2017 financial results will be released after market close on Monday, May 8, 2017. At 4:30 p.m. EDT, Coherus’ management will host a conference
Read more →CHRSC OHERUS B IOSCIENCES , I NC . E XECUTIVE C HANGE IN C ONTROL AND S EVERANCE P LAN ( AND S UMMARY P LAN D ESCRIPTION ) E FFECTIVE A PRIL 5, 2017 This Coherus BioSciences, Inc. Executive Change in Control and Severance Pl
COHERUS BIOSCIENCES, INC. EXECUTIVE CHANGE IN CONTROL AND SEVERANCE (AND SUMMARY PLAN DESCRIPTION) EFFECTIVE APRIL 5, 2017 This Coherus BioSciences, Inc. Executive Change in Control and Severance Plan (this Plan ) was established effective as of April 5, 2017 (the Effective
Read more →CHRSCoherus BioSciences Appoints Erik Wiberg as Executive Vice President of Corporate Development
REDWOOD CITY, Calif., March 27, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced the appointment of Erik Wiberg as Executive Vice President of Corporate Development. Mr. Wiberg joins Coherus with more than 30 years of experience, including more th
Read more →CHRSCoherus BioSciences Reports Fourth Quarter and Full Year 2016 Corporate Highlights and Financial Results
Coherus BioSciences Reports Fourth Quarter and Full Year 2016 Corporate Highlights and Financial Results REDWOOD CITY, Calif., March 13, 2016 Coherus BioSciences, Inc. (Nasdaq: CHRS), today reviewed corporate events and reported financial results for the fourth quarter and ful
Read more →CHRSCoherus Addresses Trade Secret Action Filed by Amgen
REDWOOD CITY, Calif., March 06, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that Amgen has filed a trade secret action in California state court on March 3, 2017 alleging trade secret misappropriation and other claims against Coherus and othe
Read more →CHRSCOHERUS ANNOUNCES CHS-1420
COHERUS ANNOUNCES CHS-1420 PHARMACOKINETIC CLINICAL BIOEQUIVALENCE STUDY MEETS PRIMARY ENDPOINT REDWOOD CITY, Calif., March 2, 2017 Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that CHS-1420, its proposed biosimilar of adalimumab (Humira ), met the primary endpoin
Read more →CHRSCoherus Announces CHS-1420 Pharmacokinetic Clinical Bioequivalence Study Meets Primary Endpoint
REDWOOD CITY, Calif., March 02, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that CHS-1420, its proposed biosimilar of adalimumab (Humira®), met the primary endpoint in a clinical pharmacokinetic (PK) bioequivalence study that compared CHS-142
Read more →CHRSCoherus BioSciences to Report Fourth Quarter and Full Year 2016 Financial Results on March 13th
REDWOOD CITY, Calif., Feb. 21, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that its fourth quarter and full year 2016 financial results will be released after market close on Monday, March 13, 2017. At 4:30 p.m. Eastern Time, Coherus’ managem
Read more →CHRSCoherus BioSciences Files Four Petitions for Inter Partes Review Against AbbVie s HUMIRA Formulation Patent 9,085,619
Coherus BioSciences Files Four Petitions for Inter Partes Review Against AbbVie s HUMIRA Formulation Patent 9,085,619 REDWOOD CITY, Calif., January 31, 2017 Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that it has filed four petitions for Inter Partes Review ( IPR
Read more →CHRSCoherus BioSciences Announces Positive Topline 24-Week Treatment Phase Three Results for CHS-1420 (HUMIRA Biosimilar Candidate) in Patients with Psoriasis
REDWOOD CITY, Calif., Jan. 10, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ:CHRS), today reported results from an ongoing 3-Part, Phase 3 clinical study of CHS-1420, an adalimumab (HUMIRA) biosimilar candidate. As previously reported, this study met its primary endp
Read more →CHRSCoherus BioSciences Management to Present at The 35th Annual J.P. Morgan Healthcare Conference
REDWOOD CITY, Calif., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that senior management will present at the 35th annual J.P. Morgan healthcare conference on Tuesday, January 10, 2017 at 2:00 p.m. PT being held in San Francisco. The
Read more →CHRSCoherus BioSciences to Present at BMO – Prescriptions for Success Healthcare Conference on December 14th
REDWOOD CITY, Calif., Dec. 07, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that management will participate in a fireside chat scheduled at the BMO – Prescriptions for Success Healthcare Conference on Wednesday, December 14th at 3:20 p.m. ET
Read more →CHRSCoherus Marketing Authorization Application to European Medicines Agency for CHS-1701 (Pegfilgrastim Biosimilar Candidate) Accepted
Coherus Marketing Authorization Application to European Medicines Agency for CHS-1701 (Pegfilgrastim Biosimilar Candidate) Accepted REDWOOD CITY, Calif., November 29, 2016 Coherus BioSciences, Inc. (NASDAQ: CHRS), today announced acceptance of a Marketing Authorization Applica
Read more →CHRSCoherus BioSciences Reports Third Quarter 2016 Operating and Financial Results Continued execution on multiple fronts positions the company strongly for the remainder of 2016 and beyond
Coherus BioSciences Reports Third Quarter 2016 Operating and Financial Results Continued execution on multiple fronts positions the company strongly for the remainder of 2016 and beyond REDWOOD CITY, Calif., November 9, 2016 Coherus BioSciences, Inc. (Nasdaq: CHRS), today rep
Read more →CHRSCoherus BioSciences Receives Decision Denying Institution of the 166 IPR Related to AbbVie s HUMIRA Formulation Management to host a call to discuss the decision
Coherus BioSciences Receives Decision Denying Institution of the 166 IPR Related to AbbVie s HUMIRA Formulation Management to host a call to discuss the decision REDWOOD CITY, Calif., November 7, 2016 -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that it has rec
Read more →CHRSCoherus BioSciences to Report Third Quarter 2016 Financial Results on November 9th
REDWOOD CITY, Calif., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that its third quarter 2016 financial results will be released on November 9, 2016. At 4:30 p.m. Eastern Time, Coherus’ management will host a conference call to discu
Read more →CHRSCoherus BioSciences Management to Present at Two Investor Healthcare Conferences in November
REDWOOD CITY, Calif., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that senior management will present at two upcoming investor healthcare conferences in November. Management participation in a fireside chat is scheduled at Credit Su
Read more →CHRSCoherus BioSciences Completes two Pharmacokinetic Bioequivalence Studies of CHS-0214
Coherus BioSciences Completes two Pharmacokinetic Bioequivalence Studies of CHS-0214 REDWOOD CITY, Calif., October 6, 2016 Coherus BioSciences, Inc. (Nasdaq: CHRS) a leading pure-play, global biosimilar company with late-stage clinical products, today announced results from tw
Read more →CHRSCoherus BioSciences Announces FDA Acceptance of 351(k) Biologics License Application to U.S. Food and Drug Administration for CHS-1701 (Pegfilgrastim Biosimilar Candidate)
Coherus BioSciences Announces FDA Acceptance of 351(k) Biologics License Application to U.S. Food and Drug Administration for CHS-1701 (Pegfilgrastim Biosimilar Candidate) REDWOOD CITY, Calif., October 6, 2016 Coherus BioSciences, Inc. (NASDAQ: CHRS), a leading pure-play, glob
Read more →CHRSCoherus BioSciences Regains Development and Commercial Rights to CHS-0214 From Shire
REDWOOD CITY, Calif., Sept. 27, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS) today announced that it has regained from Shire plc all development and commercial rights previously licensed for CHS-0214 etanercept, a biosimilar candidate to Enbrel®, for Europe, C
Read more →CHRSCoherus BioSciences Reports Second Quarter 2016 Financial and Operating Results Continued execution on multiple fronts positions the company strongly for the second-half of 2016 and beyond
Coherus BioSciences Reports Second Quarter 2016 Financial and Operating Results Continued execution on multiple fronts positions the company strongly for the second-half of 2016 and beyond REDWOOD CITY, Calif., August 9, 2016 Coherus BioSciences, Inc. (Nasdaq: CHRS), today re
Read more →CHRSCoherus BioSciences Submits 351(k) Biologics License Application to U.S. Food and Drug Administration for CHS-1701 (Pegfilgrastim Biosimilar Candidate)
REDWOOD CITY, Calif., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ:CHRS), today announced submission of the biologics license application (BLA) for CHS-1701, a pegfilgrastim (Neulasta®) biosimilar candidate, to U.S. FDA under the 351(k) pathway. The BLA su
Read more →CHRSCoherus BioSciences Announces Positive Topline Phase Three Results for CHS-1420 (Humira Biosimilar Candidate) in Patients with Psoriasis
REDWOOD CITY, Calif., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ:CHRS), today reported topline results from an ongoing Phase 3 clinical study of CHS-1420, an adalimumab (Humira®) biosimilar candidate. This study met its primary endpoint demonstrating simi
Read more →CHRSCoherus BioSciences to Report Second Quarter 2016 Financial Results on August 9th
REDWOOD CITY, Calif., July 25, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that its second quarter 2016 financial results will be released on August 9, 2016. At 4:30 p.m. Eastern Time, Coherus’ management will host a conference call to discus
Read more →CHRSCoherus Announces Positive Topline Results for CHS-1701 (Pegfilgrastim Biosimilar Candidate) Pharmacokinetic and Pharmacodynamic Biosimilarity Study BLA submission anticipated in the third quarter 2016
Coherus Announces Positive Topline Results for CHS-1701 (Pegfilgrastim Biosimilar Candidate) Pharmacokinetic and Pharmacodynamic Biosimilarity Study BLA submission anticipated in the third quarter 2016 REDWOOD CITY, Calif., July 11, 2016 Coherus BioSciences, Inc. (NASDAQ: CHR
Read more →CHRSCoherus Announces Positive Phase 2b Efficacy Data on Novel Oral Therapy in Relapsing Remitting Multiple Sclerosis Six Month Study Demonstrates Significant Reduction in Contrast-Enhancing Lesions Meeting Primary Endpoint
Coherus Announces Positive Phase 2b Efficacy Data on Novel Oral Therapy in Relapsing Remitting Multiple Sclerosis Six Month Study Demonstrates Significant Reduction in Contrast-Enhancing Lesions Meeting Primary Endpoint Safety and Tolerability Support Differentiated Product P
Read more →CHRSCoherus BioSciences Provides Update on IPRs
REDWOOD CITY, Calif., June 13, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced that it has received a favorable decision from the Patent Trial and Appeal Board (PT
Read more →CHRSCoherus BioSciences Provides Update on IPRs Patent Trial and Appeal Board Institutes Two Additional IPRs Against AbbVie s Patents
Coherus BioSciences Provides Update on IPRs Patent Trial and Appeal Board Institutes Two Additional IPRs Against AbbVie s Patents REDWOOD CITY, Calif., June 13, 2016 Coherus BioSciences, Inc. (Nasdaq: CHRS), a leading pure-play, global biosimilars company with late-stage clinic
Read more →CHRSCoherus Presents Study Results Demonstrating Equivalence of its CHS-0214 Biosimilar to Etanercept
REDWOOD CITY, Calif., June 10, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced the release of study data demonstrating the equivalence of Coherus’ etanercept biosi
Read more →CHRSCoherus BioSciences to Present at Jefferies 2016 Healthcare Conference on June 8
REDWOOD CITY, Calif., June 03, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced that it will present at the Jefferies 2016 Healthcare Conference on Wednesday, June
Read more →CHRSCoherus BioSciences Advances Differentiated IP Strategy for Humira Market Access
REDWOOD CITY, Calif., May 26, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced that the United States Patent and Trademark Office (USPTO) issued to Coherus U.S. Pat
Read more →CHRSCoherus BioSciences Provides Update on 135 IPR Patent Trial and Appeal Board Institutes
Coherus BioSciences Provides Update on 135 IPR Patent Trial and Appeal Board Institutes REDWOOD CITY, Calif., May 17, 2016 Coherus BioSciences, Inc. (Nasdaq: CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced that it has r
Read more →CHRSCoherus BioSciences Provides Update on ‘135 IPR
REDWOOD CITY, Calif., May 17, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced that it has received a favorable decision from the Patent Trial and Appeal Board (“PT
Read more →CHRSCoherus BioSciences Appoints Patrick O’Brien as Senior Vice President, Investor Relations
REDWOOD CITY, Calif., May 16, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late stage clinical, as well as pipeline products, is pleased to announce the appointment of Patrick O’Brien as Senior Vice Preside
Read more →CHRSForward looking statements Except for the historical information contained herein, the matters set forth in this presentation, including statements regarding Coherus' plans, potential opportunities, expectations, project
Coherus BioSciences Bank of America Merrill Lynch Health Care Conference May 2016 Exhibit 99.1 Forward looking statements Except for the historical information contained herein, the matters set forth in this presentation, including statements regarding Coherus' plans, potentia
Read more →CHRSCoherus BioSciences Reports First Quarter 2016 Financial and Operating Results CHS-1420 (adalimumab biosimilar) Formulation Patents to Issue in May Completed Private Convertible Financing of $100 million Received $30 mil
Coherus BioSciences Reports First Quarter 2016 Financial and Operating Results CHS-1420 (adalimumab biosimilar) Formulation Patents to Issue in May Completed Private Convertible Financing of $100 million Received $30 million Milestone Payment from Baxalta in May REDWOOD CITY
Read more →CHRSCoherus BioSciences to Present at Bank of America Merrill Lynch Health Care Conference on May 11
REDWOOD CITY, Calif., May 04, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced that it will present at the Bank of America Merrill Lynch Health Care Conference on W
Read more →CHRSCoherus BioSciences to Report First Quarter 2016 Financial Results on May 9
REDWOOD CITY, Calif., May 02, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilar company with late-stage clinical products, today announced that it has scheduled a conference call for Monday, May 9, 2016 at 1:30 p.m. PT / 4:30
Read more →CHRSCoherus BioSciences to Present at Barclays Generic Pharmaceuticals Symposium on April 6
REDWOOD CITY, Calif., March 29, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced that it will present at the Barclays Generic Pharmaceuticals Symposium on Wednesday
Read more →CHRSCoherus BioSciences to Present at Barclays Global Healthcare Conference on March 16
REDWOOD CITY, Calif., March 07, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced that it will present at the Barclays Global Healthcare Conference on Wednesday, Mar
Read more →CHRSCoherus BioSciences Announces Private Placement of $100 Million Senior Convertible Notes
REDWOOD CITY, Calif., Feb. 29, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced that it has entered into agreements for $100 million of senior convertible notes wit
Read more →CHRSCoherus BioSciences Reports Fourth Quarter and Year End 2015 Financial and Operating Results Completed Private Convertible Financing of $100 million Completed Positive Immunogenicity Registration Trial for CHS-1701 Compl
Coherus BioSciences Reports Fourth Quarter and Year End 2015 Financial and Operating Results Completed Private Convertible Financing of $100 million Completed Positive Immunogenicity Registration Trial for CHS-1701 Completed Two Positive Phase 3 Registration Trials for CHS-02
Read more →CHRSCoherus BioSciences to Present at Cowen and Company Healthcare Conference on March 8
REDWOOD CITY, Calif., Feb. 26, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced that it will present at the Cowen and Company 36th Annual Healthcare Conference on T
Read more →CHRSCoherus BioSciences to Report Fourth Quarter and Year End 2015 Financial Results on February 29
REDWOOD CITY, Calif., Feb. 15, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilar company with late-stage clinical products, today announced that it has scheduled a conference call for Monday, February 29, 2016 at 1:30 p.m. PT
Read more →CHRSCoherus BioSciences to Present at Bloomberg Intelligence Healthcare Event on February 12th
REDWOOD CITY, Calif., Feb. 05, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced that Denny Lanfear, President and Chief Executive Officer, will be a featured speake
Read more →CHRSCoherus Announces CHS-1701 (Neulasta Biosimilar) Met Both Primary Endpoints in Registration-Enabling Immunogenicity Study
Coherus Announces CHS-1701 (Neulasta Biosimilar) Met Both Primary Endpoints in Registration-Enabling Immunogenicity Study REDWOOD CITY, Calif., Feb. 1, 2016 (GLOBE NEWSWIRE) Coherus BioSciences, Inc. (NASDAQ:CHRS) today announced that CHS-1701, a proposed biosimilar of Neulast
Read more →CHRSCoherus Announces the Appointment of Jim Daly, Executive Chairman, Commercial Advisory Committee
REDWOOD CITY, Calif., Feb. 01, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today is pleased to announce the appointment of Jim Daly as Executive Chairman, Commercial Advisory
Read more →CHRSCOHERUS AND BAXALTA ANNOUNCE CHS-0214 (INVESTIGATIONAL ETANERCEPT BIOSIMILAR) MET PRIMARY EFFICACY ENDPOINT IN PHASE 3 RHEUMATOID ARTHRITIS CLINICAL STUDY (RAPSODY) REDWOOD CITY, Calif., and
COHERUS AND BAXALTA ANNOUNCE CHS-0214 (INVESTIGATIONAL ETANERCEPT BIOSIMILAR) MET PRIMARY EFFICACY ENDPOINT IN PHASE 3 RHEUMATOID ARTHRITIS CLINICAL STUDY REDWOOD CITY, Calif., and BANNOCKBURN, Ill., Jan. 11, 2016 (GLOBE NEWSWIRE) Coherus BioSciences, Inc. (NASDAQ:CHRS) and Bax
Read more →CHRSCoherus BioSciences to Present at J.P. Morgan Healthcare Conference on January 11
REDWOOD CITY, Calif., Jan. 04, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced that it will present at the 34th Annual J.P. Morgan Healthcare Conference on Monday,
Read more →CHRSCoherus BioSciences Signs Strategic Manufacturing Agreement with KBI Biopharma for Commercial Supply of CHS-1701
Coherus BioSciences Signs Strategic Manufacturing Agreement with KBI Biopharma for Commercial Supply of CHS-1701 REDWOOD CITY, Calif., December 21, 2015 Coherus BioSciences, Inc. (Nasdaq: CHRS), a leading pure-play, global biosimilars company with late-stage clinical products,
Read more →CHRSCoherus BioSciences Reports Update to CHS-1701 Program Pegfilgrastim Follow-on PK/PD Study Added to Bolster BLA Submission Package
Coherus BioSciences Reports Update to CHS-1701 Program Pegfilgrastim Follow-on PK/PD Study Added to Bolster BLA Submission Package REDWOOD CITY, Calif., December 8, 2015 Coherus BioSciences, Inc. (Nasdaq: CHRS), a leading pure-play, global biosimilars company with late-stage c
Read more →CHRSCoherus BioSciences to Present at Jefferies Autumn 2015 Global Healthcare Conference on November 18
REDWOOD CITY, Calif., Nov. 10, 2015 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilar platform company with late-stage clinical products, today announced that it will present at the Jefferies Autumn 2015 Global Healthcare Conferen
Read more →CHRSCoherus BioSciences Reports Third Quarter 2015 Financial and Operating Results and Corporate Events Pegfilgrastim PK/PD Study Completed and Adalimumab Phase 3 Study Initiated
Coherus BioSciences Reports Third Quarter 2015 Financial and Operating Results and Corporate Events Pegfilgrastim PK/PD Study Completed and Adalimumab Phase 3 Study Initiated REDWOOD CITY, Calif., November 9, 2015 Coherus BioSciences, Inc. (Nasdaq: CHRS), a leading pure-play,
Read more →CHRSCoherus and Baxalta Announce CHS-0214 (Investigational Etanercept Biosimilar) Met Primary Efficacy Endpoints in Phase 3 Psoriasis Clinical Study (RaPsODY)
REDWOOD CITY, Calif. and BANNOCKBURN, Ill., Nov. 09, 2015 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ:CHRS) and Baxalta Incorporated (NYSE:BXLT) today announced that CHS-0214, a proposed biosimilar of Enbrel® (etanercept), met its primary endpoints in a confirmatory, do
Read more →CHRSCoherus BioSciences to Present at Credit Suisse Healthcare Conference on November 10
REDWOOD CITY, Calif., Oct. 28, 2015 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced that it will present at the Credit Suisse 24th Annual Healthcare Conference on Tuesd
Read more →CHRSCoherus BioSciences to Present at Bloomberg Biosimilars Conference on November 2
REDWOOD CITY, Calif., Oct. 27, 2015 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced that it will participate in several panel discussions regarding development, regulat
Read more →CHRSCoherus BioSciences to Report Third Quarter 2015 Financial Results on November 9
REDWOOD CITY, Calif., Oct. 26, 2015 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced that it has scheduled a conference call for Monday, November 9, 2015 at 1:30 p.m. PT
Read more →CHRSCoherus Announces Topline Results of CHS-1701 Pharmacokinetic and Pharmacodynamic Biosimilarity Study BLA submission targeted for the first quarter of 2016
Coherus Announces Topline Results of CHS-1701 Pharmacokinetic and Pharmacodynamic Biosimilarity Study BLA submission targeted for the first quarter of 2016 REDWOOD CITY, Calif., October 1, 2015 Coherus BioSciences, Inc. (NASDAQ: CHRS), a leading pure-play, global biosimilars co
Read more →CHRSCoherus Appoints Juliana M. Reed, Vice President, Government Affairs
REDWOOD CITY, Calif., Sept. 9, 2015 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today is pleased to announce the appointment of Juliana M. Reed as Vice President, Government Affair
Read more →CHRSCoherus BioSciences to Present at Morgan Stanley Global Healthcare Conference on September 17
REDWOOD CITY, Calif., Sept. 4, 2015 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced that it will participate in a fireside chat at the Morgan Stanley Global Healthcare
Read more →CHRSCoherus Provides Updates on Clinical Studies Increases Enrollment in CHS-1701 Immunogenicity Study Initiated Enrollment in CHS-1420 Phase 3 Study
Coherus Provides Updates on Clinical Studies Increases Enrollment in CHS-1701 Immunogenicity Study Initiated Enrollment in CHS-1420 Phase 3 Study REDWOOD CITY, Calif., September 3, 2015 Coherus BioSciences, Inc. (NASDAQ: CHRS), a leading pure-play, global biosimilars company w
Read more →CHRSCoherus Provides Updates on Clinical Studies
Increases Enrollment in CHS-1701 Immunogenicity Study Initiated Enrollment in CHS-1420 Phase 3 Study REDWOOD CITY, Calif., Sept. 3, 2015 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ:CHRS), a leading pure-play, global biosimilars company with late-stage clinical product
Read more →CHRSCoherus BioSciences Reports Second Quarter 2015 Financial and Operating Results Pegfilgrastim BLA-Enabling Studies Progressing and Etanercept Phase 3 Studies Enrolled
Coherus BioSciences Reports Second Quarter 2015 Financial and Operating Results Pegfilgrastim BLA-Enabling Studies Progressing and Etanercept Phase 3 Studies Enrolled REDWOOD CITY, Calif., August 10, 2015 Coherus BioSciences, Inc. (Nasdaq: CHRS), a leading pure-play, global bio
Read more →CHRSCoherus BioSciences to Report Second Quarter 2015 Financial Results on August 10
REDWOOD CITY, Calif., July 28, 2015 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced that it has scheduled a conference call for Monday, August 10, 2015 at 1:30 p.m. PT
Read more →CHRSCoherus BioSciences to Present at Jefferies Healthcare Conference on June 3
REDWOOD CITY, Calif., May 27, 2015 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced that it will present at the Jefferies 2015 Global Healthcare Conference on Wednesday,
Read more →CHRSCoherus BioSciences Reports First Quarter 2015 Financial and Operating Results Pegfilgrastim Progressing to BLA-Enabling Studies
Coherus BioSciences Reports First Quarter 2015 Financial and Operating Results Pegfilgrastim Progressing to BLA-Enabling Studies REDWOOD CITY, Calif., May 11, 2015 Coherus BioSciences, Inc. (Nasdaq: CHRS), a leading pure-play, global biosimilars company with late-stage clinica
Read more →CHRSCoherus BioSciences to Report First Quarter 2015 Financial Results on May 11
REDWOOD CITY, Calif., May 4, 2015 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced that it has scheduled a conference call for Monday, May 11, 2015 at 1:30 p.m. PT / 4:3
Read more →CHRSCoherus BioSciences to Present at Deutsche Bank Health Care Conference on May 7
REDWOOD CITY, Calif., April 30, 2015 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced that it will present at the Deutsche Bank 40th Annual Health Care Conference on Thu
Read more →CHRSCoherus BioSciences and Baxter Announce Amendment to Etanercept Biosimilar Collaboration Agreement REDWOOD CITY, Calif. and DEERFIELD, Ill., (
Coherus BioSciences and Baxter Announce Amendment to Etanercept Biosimilar Collaboration Agreement REDWOOD CITY, Calif. and DEERFIELD, Ill., (April 15, 2015) Coherus BioSciences, Inc. (Nasdaq: CHRS) and Baxter International Inc. (NYSE:BAX) today announced that they have amended
Read more →CHRSCoherus Prices Upsized Public Offering of $120.0 Million of Common Stock
REDWOOD CITY, Calif., March 31, 2015 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced the pricing of its underwritten public offering of 4,137,931 shares of its common s
Read more →CHRSCoherus BioSciences Reports Fourth Quarter and Year End 2014 Financial and Operating Results Strong Clinical Performance and Financial Milestones Achieved
Coherus BioSciences Reports Fourth Quarter and Year End 2014 Financial and Operating Results Strong Clinical Performance and Financial Milestones Achieved REDWOOD CITY, Calif., March 23, 2015 - Coherus BioSciences, Inc. (Nasdaq: CHRS), a leading pure-play, global biosimilars c
Read more →CHRSCoherus Finalizes CHS-1701 BLA Enabling Clinical Program and Initiates Pivotal Pharmacokinetic and Pharmacodynamic Study
Coherus Finalizes CHS-1701 BLA Enabling Clinical Program and Initiates Pivotal Pharmacokinetic and Pharmacodynamic Study REDWOOD CITY, Calif., March 17, 2015 Coherus BioSciences, Inc. (NASDAQ: CHRS), a leading pure-play, global biosimilars company with late-stage clinical prod
Read more →CHRSCoherus BioSciences to Report Fourth Quarter and Year End 2014 Financial Results on March 23
REDWOOD CITY, Calif., March 16, 2015 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a late-stage clinical biologics platform company focused on the global biosimilar market, today announced that it has scheduled a conference call for Monday, March 23, 2015 at 1:30 p
Read more →CHRSCoherus BioSciences to Present at Cowen and Company Health Care Conference on March 2
REDWOOD CITY, Calif., Feb. 23, 2015 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a late-stage clinical biologics platform company focused on the global biosimilar market, today announced that it will present at the Cowen and Company 35th Annual Health Care Confere
Read more →CHRSCoherus BioSciences to Present at Leerink Healthcare Conference on February 11
REDWOOD CITY, Calif., Feb. 4, 2015 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a late-stage clinical biologics platform company focused on the global biosimilar market, today announced that it will participate in a fireside chat at the 2015 Leerink Global Healthc
Read more →CHRSCoherus BioSciences Reports Third Quarter 2014 Financial and Operating Results Management to Host Call at 4:30 pm ET to Discuss Quarter and Pipeline Advances
Coherus BioSciences Reports Third Quarter 2014 Financial and Operating Results Management to Host Call at 4:30 pm ET to Discuss Quarter and Pipeline Advances REDWOOD CITY, Calif., Dec. 15, 2014 (GLOBE NEWSWIRE) Coherus BioSciences, Inc. (Nasdaq: CHRS), a late-stage clinical bio
Read more →CHRSCoherus BioSciences to Present at the J.P. Morgan Healthcare Conference on January 12
REDWOOD CITY, Calif., Dec. 8, 2014 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a late-stage clinical biologics platform company focused on the global biosimilar market, today announced that it will present at the 33rd Annual J.P. Morgan Healthcare Conference on M
Read more →CHRSCoherus BioSciences to Host Earnings Conference Call on December 15
REDWOOD CITY, Calif., Dec. 4, 2014 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a late-stage clinical biologics platform company focused on the global biosimilar market, today announced that it has scheduled a conference call for Monday, December 15, 2014, at 1:30
Read more →CHRSCoherus BioSciences Announces Closing of Initial Public Offering and Exercise of Underwriters Option to Purchase Additional Shares Redwood City, California
Coherus BioSciences Announces Closing of Initial Public Offering and Exercise of Underwriters Option to Purchase Additional Shares Redwood City, California November 12, 2014 Coherus BioSciences, Inc. announced today the closing of its initial public offering of 6,803,702 share
Read more →CHRSCoherus BioSciences Prices Initial Public Offering of $85 Million of Common Stock
REDWOOD CITY, Calif., Nov. 6, 2014 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS) announced today the pricing of its initial public offering of 6,296,300 shares of its common stock at a public offering price of $13.50 per share, before underwriting discounts, commiss
Read more →Competitive Position
How CHRS ranks across every disease it competes inCompetitive Position is a premium feature
See how CHRS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial